

**NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)**

# **Ovarian Cancer**

## **Including Fallopian Tube Cancer and Primary Peritoneal Cancer**

Version 2.2013

**NCCN.org**

NCCN Guidelines for Patients™ are available at [www.nccn.com](http://www.nccn.com).

**Continue**



National  
Comprehensive  
Cancer  
Network®

# NCCN Guidelines Version 2.2013 Panel Members

## Ovarian Cancer

[NCCN Guidelines Index](#)  
[Ovarian Cancer TOC](#)  
[Discussion](#)

\* Robert J. Morgan, Jr., MD/Chair ‡  
City of Hope Comprehensive Cancer Center

\* Ronald D. Alvarez, MD Ω  
University of Alabama at Birmingham  
Comprehensive Cancer Center

\* Deborah K. Armstrong, MD †  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

Robert A. Burger, MD Ω  
Fox Chase Cancer Center

Lee-may Chen, MD Ω  
UCSF Helen Diller Family  
Comprehensive Cancer Center

Larry Copeland, MD Ω  
The Ohio State University Comprehensive  
Cancer Center - James Cancer Hospital  
and Solove Research Institute

\* Marta Ann Crispens, MD Ω  
Vanderbilt-Ingram Cancer Center

David M. Gershenson, MD Ω  
The University of Texas  
MD Anderson Cancer Center

Heidi J. Gray, MD Ω  
University of Washington Medical Center/  
Seattle Cancer Care Alliance

\* Ardeshir Hakam, MD ≠  
Moffitt Cancer Center

\* Laura J. Havrilesky, MD Ω  
Duke Cancer Institute

Carolyn Johnston, MD Ω  
University of Michigan  
Comprehensive Cancer Center

\* Shashikant Lele, MD Ω  
Roswell Park Cancer Institute

Lainie Martin, MD †  
Fox Chase Cancer Center

\* Ursula A. Matulonis, MD †  
Dana-Farber/Brigham and Women's  
Cancer Center

David M. O'Malley, MD Ω  
The Ohio State University Comprehensive  
Cancer Center - James Cancer Hospital  
and Solove Research Institute

Richard T. Penson, MD, MRCP †  
Massachusetts General Hospital  
Cancer Center

\* Matthew A. Powell, MD Ω  
Siteman Cancer Center at Barnes-  
Jewish Hospital and Washington  
University School of Medicine

Steven W. Remmenga, MD Ω  
UNMC Eppley Cancer Center at  
The Nebraska Medical Center

Paul Sabbatini, MD † †  
Memorial Sloan-Kettering Cancer Center

Joseph T. Santoso, MD Ω  
St. Jude Children's Research Hospital/  
University of Tennessee Cancer Institute

\* Julian C. Schink, MD Ω  
Robert H. Lurie Comprehensive Cancer  
Center of Northwestern University

\* Nelson Teng, MD, PhD Ω  
Stanford Cancer Institute

\* Theresa L. Werner, MD † ‡  
Huntsman Cancer Institute  
at the University of Utah

**NCCN**  
Mary Dwyer, MS  
Miranda Hughes, PhD

**Continue**

Ω Gynecology oncology  
‡ Hematology/Hematology oncology  
† Medical oncology  
‡ Internal medicine  
≠ Pathology  
\* Writing committee member

[NCCN Guidelines Panel Disclosures](#)



### [NCCN Ovarian Cancer Panel Members](#) [Summary of the Guidelines Updates](#)

Epithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer:

[Clinical Presentation, Workup, Primary Treatment \(OV-1\)](#)

[Diagnosis by Previous Surgery: Findings and Primary Treatment \(OV-2\)](#)

[Pathologic Staging, Primary Chemotherapy/Primary Adjuvant Therapy \(OV-3\)](#)

[Post-Primary Treatment: Secondary Adjuvant Therapy \(OV-4\)](#)

[Monitoring/Follow-Up, Recurrent Disease \(OV-5\)](#)

[Disease Status, Therapy for Persistent Disease or Recurrence \(OV-6\)](#)

Borderline Epithelial Ovarian Cancer (Low Malignant Potential):

[Clinical Presentation, Primary Treatment \(OV-7\)](#)

[Monitoring/Follow-Up, Recurrent Disease, Recurrence Therapy \(OV-9\)](#)

[Principles of Primary Surgery \(OV-A\)](#)

[Principles of Chemotherapy \(Ovarian, Fallopian Tube, and Primary Peritoneal Cancer\) \(OV-B\)](#)

[Management of Drug Reactions \(OV-C\)](#)

[Primary Chemotherapy/Primary Adjuvant Therapy Regimens for Stage II-IV \(OV-D\)](#)

[Acceptable Recurrence Therapies \(OV-E\)](#)

Less Common Ovarian Histopathologies:

[Clinical Presentation, Workup, Diagnosis \(LCOH-1\)](#)

[Malignant Germ Cell Tumors \(LCOH-2\)](#)

[Malignant Sex Cord-Stromal Tumors \(LCOH-4\)](#)

[Carcinosarcoma \(Malignant Mixed Müllerian Tumors\) \(LCOH-5\)](#)

[Sex Cord-Stromal Tumors - WHO Histologic Classification \(LCOH-A\)](#)

[Surveillance for Germ Cell and Sex Cord-Stromal Tumors \(LCOH-B\)](#)

[Acceptable Recurrence Therapies \(LCOH-C\)](#)

**Clinical Trials:** NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here: nccn.org/clinical\\_trials/physician.html](#).

**NCCN Categories of Evidence and Consensus:** All recommendations are category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#).

**NCCN Guidelines for Patients™ are available at [www.nccn.com](http://www.nccn.com).**

### [Staging \(ST-1\)](#)

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2013.



Updates to the 1.2013 version of the NCCN Guidelines for Ovarian Cancer from the 1.2013 version include:

#### [MS-1](#)

- The discussion section was updated to reflect the changes in the algorithm.

Updates to the 1.2013 version of the NCCN Guidelines for Ovarian Cancer from the 3.2012 version include:

#### [OV-1](#)

- Workup
  - “Ultrasound and/or abdominal/pelvic CT” was modified to include “as clinically indicated.”
- Footnote “c” was added: “PET/CT scan may be indicated for indeterminate lesions if results will alter management.”

#### [OV-2](#)

- The finding of “Suspected stage IA or IB, grade 3 stage IC” was modified as: “...grade 3 *or clear cell* or stage IC.”
- Footnote was removed: “Clear-cell pathology is grade 3.” (Also for OV-3.)

#### [OV-3](#)

- Stage 1A or 1B, Grade 3 was modified to include: “or clear cell.”
- Footnote was removed: “The NCCN Ovarian Cancer panel recognizes that data for first-line and maintenance bevacizumab are becoming available and encourages participation in clinical trials.” (Also for OV-D.)

#### [OV-4](#)

- For Secondary Adjuvant Therapy, “Clinical trial” was moved to be the first option.

#### [OV-6](#)

- Disease Status,
  - For “Progression, stable, or persistent disease on primary chemotherapy,” the option of “supportive care only” was modified by adding “palliative” and a corresponding link, “See NCCN Guidelines for Palliative Care.”

#### [OV-7](#)

- Clinical presentation and primary treatment of “pelvic mass” was incorporated with “diagnosis of low malignant potential lesion with institutional pathology review.”

#### [OV-8](#)

- For primary treatment options that include “comprehensive surgical staging,” the category 2B recommendation was clarified to include “for staging.”
- Footnotes:
  - Footnote “t” was added: “Observation is a reasonable option regardless of whether fertility is desired.”
  - Footnote “u” was added: “For pathologically proven LMP, lymph node evaluation may be considered on a case-by-case basis.”

#### [OV-A 2 of 3](#)

- “Procedures that may be considered for optimal surgical cytoreduction” was modified by adding: “appendectomy.”
- Special circumstances, 1st bullet was modified as: “In ~~Stage I~~ *early-stage* disease...”

#### [OV-D](#)

- Number “1” was modified as: “Paclitaxel 135 mg/m<sup>2</sup> IV continuous infusion over 3 *or* 24 h Day 1; cisplatin 75-100 mg/m<sup>2</sup> IP, Day 2 after IV paclitaxel; paclitaxel 60 mg/m<sup>2</sup> IP Day 8 (~~max BSA 2.0 m<sup>2</sup>~~)...”
- Footnotes:
  - Footnote “2” was added: “The published randomized trial regimen used IV continuous infusion paclitaxel over 24 h.”
  - Footnote “3” was added: “Due to changes in creatinine methodology, changes regarding carboplatin dosing can be considered. See FDA carboplatin dosing statement.”

#### [OV-E](#)

- Under Cytotoxic therapy, an additional preferred regimen option was added: “Carboplatin/gemcitabine/bevacizumab” as a category 2B recommendation with a corresponding footnote, “In patients who have not previously received bevacizumab.”

#### [LCOH-B](#)

- A new page was added: “Surveillance for Germ Cell and Sex Cord-Stromal Tumors” and links to this page were added throughout the “Less Common Ovarian Histopathologies” algorithms.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### CLINICAL PRESENTATION

Suspicious<sup>a</sup>/palpable pelvic mass detected on abdominal/pelvic exam and/or ascites, abdominal distention, and/or Symptoms such as bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, or urinary symptoms (urgency or frequency)<sup>b</sup> without other obvious source of malignancy

### WORKUP

- Obtain family history and consider family history evaluation ([See NCCN Guidelines for Genetic/Familial High-Risk Assessment](#) and [NCCN Guidelines for Colorectal Cancer Screening](#))
- Abdominal/pelvic exam
- Chest imaging
- Complete blood count (CBC), chemistry profile with liver function test (LFT)
- GI evaluation as clinically indicated
- Ultrasound and/or abdominal/pelvic CT as clinically indicated<sup>c</sup>
- CA-125 or other tumor markers as clinically indicated<sup>d</sup>

### PRIMARY TREATMENT<sup>e,f</sup>

Laparotomy/hysterectomy (TAH)/bilateral salpingo-oophorectomy (BSO) with comprehensive staging<sup>g</sup> or unilateral salpingo-oophorectomy (USO) (clinical stage 1A or 1C, all grades with comprehensive staging if patient desires fertility) or  
Cytoreductive surgery<sup>g</sup> if clinical stage II, III, or IV or  
Consider neoadjuvant chemotherapy<sup>h</sup> (category 1)/primary interval cytoreduction<sup>e</sup> (diagnosis by fine needle aspiration [FNA], biopsy, or paracentesis) for patients with bulky stage III/IV who are poor surgical candidates due to high-risk comorbidity conditions or disease factors

[See Pathologic Staging \(OV-3\)](#)

Diagnosis by previous surgery or tissue biopsy (cytopathology)

- Obtain family history and consider family history evaluation ([See NCCN Guidelines for Genetic/Familial High-Risk Assessment](#) and [for Colorectal Cancer Screening](#))
- Chest imaging
- CBC, chemistry profile with LFTs
- Institutional pathology review
- Ultrasound and/or abdominal/pelvic CT as clinically indicated<sup>c</sup>
- CA-125 or other tumor markers as clinically indicated<sup>d</sup>

[See Findings and Primary Treatment \(OV-2\)](#)

<sup>a</sup>Im SS, Gordon AN, Buttin BM, et al. *Obstet Gynecol* 2005;105:35-41. [See Discussion](#).

<sup>b</sup>Goff BA, Mandel L, Drescher CW, et al. *Cancer* 2007;109:221-227.

<sup>c</sup>PET/CT scan may be indicated for indeterminate lesions if results will alter management.

<sup>d</sup>See Discussion for usefulness of diagnostic tests.

<sup>e</sup>Standard recommendation includes a patient evaluation by a gynecologic oncologist prior to initiating chemotherapy. Published data demonstrate that primary assessment and debulking by a gynecologic oncologist result in a survival advantage. Patients being evaluated for neoadjuvant chemotherapy should be seen by a fellowship-trained gynecologist oncologist prior to being considered a poor surgical candidate.

<sup>f</sup>All women undergoing surgery for ovarian cancer should be counseled about the clinical benefit associated with combined IV and IP chemotherapy administration prior to surgery. [NCI Clinical Announcement](#).

<sup>g</sup>[See Principles of Primary Surgery \(OV-A\)](#).

<sup>h</sup>[See Principles of Chemotherapy \(OV-B\)](#) and [Management of Drug Reactions \(OV-C\)](#).

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### DIAGNOSIS BY PREVIOUS SURGERY



<sup>e</sup>Standard recommendation includes a patient evaluation by a gynecologic oncologist prior to initiating chemotherapy. Published data demonstrate that primary assessment and debulking by a gynecologic oncologist result in a survival advantage. Patients being evaluated for neoadjuvant chemotherapy should be seen by a fellowship-trained gynecologist oncologist prior to being considered a poor nonsurgical candidate.

<sup>g</sup>See [Principles of Primary Surgery \(OV-A\)](#).

<sup>h</sup>See [Principles of Chemotherapy \(OV-B\)](#) and [Management of Drug Reactions \(OV-C\)](#).

<sup>i</sup>Based on clinical judgement of gynecologic oncologist, surgery may be performed after 6 cycles.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### **PATHOLOGIC STAGING**

### **PRIMARY CHEMOTHERAPY/PRIMARY ADJUVANT THERAPY<sup>j</sup>**



<sup>f</sup>All women undergoing surgery for ovarian cancer should be counseled about the clinical benefit associated with combined IV and IP chemotherapy administration prior to surgery. [NCI Clinical Announcement](#).

<sup>g</sup>[See Principles of Primary Surgery \(OV-A\)](#).

<sup>h</sup>[See Principles of Chemotherapy \(OV-B\)](#) and [Management of Drug Reactions \(OV-C\)](#).

<sup>j</sup>Patients receiving primary chemotherapy will be monitored as follows:

1. Pelvic exams at least every 2-3 cycles
2. Interim CBC with platelets as indicated
3. Chemistry profiles if indicated
4. CA-125 levels or other tumor markers as clinically indicated prior to each cycle of chemotherapy
5. Radiographic imaging if indicated

<sup>k</sup>See specific regimens on [Primary Chemotherapy/Primary Adjuvant Therapy Regimens for Stage II-IV \(OV-D\)](#).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### STAGE II, III, IV POST-PRIMARY TREATMENT

### SECONDARY ADJUVANT THERAPY



<sup>l</sup>No objective evidence of disease (ie, negative physical exam, negative CA-125, negative CT with <1 cm lymph nodes).

<sup>m</sup>[See Discussion](#) for dosing.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.






# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### STAGE I-IV COMPLETE RESPONSE



<sup>n</sup>There are data regarding the utility of CA-125 for monitoring of ovarian cancer after completion of primary therapy. See [The Society of Gynecologic Oncology \(SGO\) position statement](#) and [Discussion](#).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### DISEASE STATUS

### THERAPY FOR PERSISTENT DISEASE OR RECURRENCE<sup>o,p,q</sup>

Progression, stable, or persistent disease on primary chemotherapy

Clinical trial<sup>r</sup>  
or  
Supportive/palliative care only  
([See NCCN Guidelines for Palliative Care](#))  
or  
Recurrence therapy<sup>o,q</sup>

Complete remission and relapse <6 mo after stopping chemotherapy

or

Stage II, III, and IV with partial response

Clinical trial<sup>r</sup>  
or  
Recurrence therapy<sup>o,q</sup>  
or  
Observe (category 2B)

Complete remission and relapse >6 mo after stopping chemotherapy

Radiographic and/or clinical relapse

Consider secondary cytoreductive surgery<sup>g</sup>

Clinical trial<sup>r</sup>  
or  
Combination platinum-based chemotherapy<sup>o,q</sup> preferred for first recurrence (category 1)  
or  
Recurrence therapy<sup>o,q</sup>

Biochemical relapse (rising CA-125 and no radiographic evidence of disease)

Clinical trial<sup>r</sup>  
or  
Delay treatment until clinical relapse  
or  
Immediate treatment for recurrent disease (recurrence therapy<sup>q</sup>) (category 2B)

<sup>g</sup>[See Principles of Primary Surgery \(OV-A\).](#)

<sup>o</sup>Patients who progress on 2 consecutive therapy regimens without evidence of clinical benefits have diminished likelihood of benefitting from additional therapy. Decisions to offer clinical trials, supportive care only, or additional therapy should be made on a highly individual basis.

<sup>p</sup>[See Ancillary Palliative Surgical Procedures in Principles of Primary Surgery \(OV-A\).](#)

<sup>q</sup>[See Acceptable Recurrence Therapies \(OV-E\).](#)

<sup>r</sup>Clinical trials with newer agents should be strongly considered.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 2.2013

## Borderline Epithelial Ovarian Cancer (Low Malignant Potential)

### CLINICAL PRESENTATION

### PRIMARY TREATMENT<sup>s</sup>



<sup>g</sup>See Principles of Primary Surgery (OV-A).

<sup>s</sup>Standard recommendation includes a patient evaluation by a gynecologic oncologist.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 2.2013

## Borderline Epithelial Ovarian Cancer (Low Malignant Potential)

### CLINICAL PRESENTATION

### PRIMARY TREATMENT<sup>s</sup>



<sup>g</sup>See Principles of Primary Surgery (OV-A).

<sup>s</sup>Standard recommendation includes a patient evaluation by a gynecologic oncologist.

<sup>t</sup>Observation is a reasonable option regardless of whether fertility is desired.

<sup>u</sup>For pathologically proven LMP, lymph node evaluation may be considered on a case-by-case basis.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Borderline Epithelial Ovarian Cancer (Low Malignant Potential)

### MONITORING/FOLLOW-UP

- Visits every 3-6 mo for up to 5 y, then annually
- Physical exam including pelvic exam
- CA-125<sup>n</sup> or other tumor markers every visit if initially elevated
- After completion of childbearing in patients who underwent USO, consider completion surgery (category 2B)
- CBC, chemistry profile as indicated
- Ultrasound as indicated for patients with fertility-sparing surgery

### RECURRENT DISEASE

Clinical relapse

Surgical evaluation  
+ debulking if appropriate

Noninvasive disease

→ Observe

Invasive disease

→ Treatment as epithelial ovarian cancer (category 2B)  
([See OV-3](#))

<sup>n</sup>There are data regarding the utility of CA-125 for monitoring of ovarian cancer after completion of primary therapy. See [The Society of Gynecologic Oncology \(SGO\) position statement](#) and [Discussion](#).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### PRINCIPLES OF PRIMARY SURGERY (1 of 3)<sup>1,2</sup>

- In general, a vertical midline abdominal incision should be used in patients with a suspected malignant ovarian neoplasm.<sup>2</sup> Intraoperative pathologic evaluation with frozen sections may assist in management.
- Quantify the extent of initial and residual disease, and document in operative notes.

#### Ovarian cancer apparently confined to an ovary or to the pelvis

- The following procedures should be considered part of the surgical management of patients with ovarian cancer apparently confined to an ovary or to the pelvis:
  - On entering the abdomen, aspiration of ascites or peritoneal lavage should be performed for peritoneal cytologic examinations.
  - All peritoneal surfaces should be visualized, and any peritoneal surface or adhesion suspicious for harboring metastasis should be selectively excised or biopsied. In the absence of any suspicious areas, random peritoneal biopsies should be taken from the pelvis, paracolic gutters, and undersurfaces of the diaphragm (diaphragm scraping for Papanicolaou stain is an acceptable alternative).
  - Hysterectomy, bilateral salpingectomy, and bilateral oophorectomy should be performed with every effort made to keep an encapsulated mass intact during removal.
  - USO for patients desiring to preserve fertility may be considered in select patients. ([See OV-A 2 of 3](#))
  - Omentectomy should be performed.
  - Aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels.
  - Pelvic lymph nodes should be dissected. Removal of lymph nodes overlying and medial to the external iliac and hypogastric vessels, from the obturator fossa anterior to the obturator nerve, and overlying and anterolateral to the common iliac vessel is preferred.
  - In LMP, although data show upstaging with lymphadenectomy and omentectomy, other data show that this surgery does not affect overall survival.

#### Ovarian cancer involving the upper abdomen

- In general, the following procedures should be part of the surgical management of patients with ovarian cancer involving the upper abdomen in an effort to achieve maximal cytoreduction. Residual disease <1 cm defines optimal cytoreduction; however, maximal effort should be made to remove all gross disease.
  - Aspiration of ascites or peritoneal lavage should be performed for peritoneal cytologic examinations. For obvious disease beyond ovaries, cytologic assessment of ascites and/or lavage specimens would not alter stage or management.
  - Hysterectomy, bilateral salpingectomy, and bilateral oophorectomy should be performed.
  - All involved omentum should be removed.
  - Suspicious and/or enlarged nodes should be resected, if possible.
  - Those patients with tumor nodules outside the pelvis ≤2 cm (presumed stage IIIB) should have bilateral pelvic and para-aortic lymph node dissection as previously described.

<sup>1</sup>Fleming GF, Ronnett BM, Seidman J, et al: Epithelial ovarian cancer. In Barakat RR, Markman M, Randall ME (eds): Principles and Practice of Gynecologic Oncology, 5th ed, Philadelphia, Lippincott Williams & Wilkins, 2009:763-835. Amended by panel.

<sup>2</sup>It is recommended that a gynecologic oncologist perform primary surgery (category 1).

[Continued on OV-A 2 of 3](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### PRINCIPLES OF PRIMARY SURGERY (2 of 3)<sup>1</sup>

- Procedures that may be considered for optimal surgical cytoreduction (in all stages) may include:
  - Radical pelvic dissection
  - Bowel resection
  - Diaphragm or other peritoneal surface stripping
  - Splenectomy
  - Partial hepatectomy
  - Cholecystectomy
  - Partial gastrectomy
  - Partial cystectomy
  - Ureteroneocystostomy
  - Distal pancreatectomy
  - Appendectomy

#### Special Circumstances

- In early-stage disease, minimally invasive techniques may be considered to achieve the surgical principles described on [OV-A 1 of 3](#). Minimally invasive surgery performed by an experienced gynecologic oncologist may be considered in selected patients, particularly for an incidental finding of ovarian cancer during prophylactic oophorectomy. [See the College of American Pathologists, Protocol for the Examination of Specimens from Patients with Carcinoma of the Ovary](#).
- For patients with apparent early-stage disease and/or good risk tumors (early-stage invasive epithelial tumors, LMP lesion, malignant germ cell tumors, or malignant sex cord-stromal tumors) who wish to preserve fertility, USO preserving the uterus and contralateral ovary (fertility-sparing surgery) can be considered. Comprehensive surgical staging should still be performed to rule out occult higher stage disease.
- Primary invasive mucinous tumors of the ovary are uncommon; thus, the upper and lower GI tract should be carefully evaluated to rule out an occult GI primary with ovarian metastases.
- Appendectomy should be performed in all mucinous tumors and considered in all patients with epithelial malignancies suspicious for involvement of the appendix by metastases.
- Patients with low-volume residual disease after surgical cytoreduction for invasive epithelial ovarian or peritoneal cancer are potential candidates for IP therapy. In these patients, consideration should be given to placement of IP catheter with initial surgery.

[Continued on OV-A 3 of 3](#)

<sup>1</sup>Fleming GF, Ronnett BM, Seidman J, et al: Epithelial ovarian cancer. In Barakat RR, Markman M, Randall ME (eds): Principles and Practice of Gynecologic Oncology, 5th ed, Philadelphia, Lippincott Williams & Wilkins, 2009:763-835. Amended by panel.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### PRINCIPLES OF PRIMARY SURGERY (3 of 3)

#### • Ancillary Palliative Surgical Procedures

These procedures may be appropriate in select patients:

- ▶ Paracentesis
- ▶ Thoracentesis/pleurodesis
- ▶ Ureteral stents/nephrostomy
- ▶ Surgical relief of intestinal obstruction
- ▶ Gastrostomy tube
- ▶ Vascular access device
- ▶ Indwelling peritoneal or pleural catheter
- ▶ Intestinal stents
- ▶ Video-assisted thoracoscopy

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.





# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### PRINCIPLES OF CHEMOTHERAPY (FOR OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCER) (1 of 2)

#### General

- Patients with ovarian, fallopian tube, or peritoneal cancer should be encouraged to participate in clinical trials during all aspects of their diagnosis and treatment.
- Goals of systemic therapy should be discussed with patients prior to initiation of any therapy.
- Prior to recommending chemotherapy, requirements for adequate organ function and performance status should be met.
- Patients should be observed closely and treated for any complications during chemotherapy. Appropriate blood chemistry tests should be monitored. Appropriate dose reductions and modifications of chemotherapy should be performed depending on toxicities experienced and goals of therapy.
- After completion of chemotherapy, patients should be assessed for response during and following treatment and monitored for any long-term complications.
- Chemosensitivity/resistance and/or other biomarker assays are being used in some NCCN Member Institutions for decisions related to future chemotherapy in situations where there are multiple equivalent chemotherapy options available. The current level of evidence is not sufficient to supplant standard-of-care chemotherapy. (category 3)

#### For patients with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer:

- If they are eligible for chemotherapy, patients should be informed about the different options that are available--that is, IV chemotherapy, a combination of IP and IV chemotherapy, or a clinical trial--so they can decide which is the most the appropriate option. ([See OV-D](#) for dosing and schedule of these regimens).
- Prior to the administration of the combined IP and IV regimen, patients must be apprised of the increased toxicities with the combined regimen when compared to using IV chemotherapy alone (increased myelosuppression, renal toxicities, abdominal pain, neuropathy, gastrointestinal toxicities, metabolic toxicities, and hepatic toxicities).
- Patients considered for the IP cisplatin and IP/IV paclitaxel regimen should have normal renal function prior to starting, a medically appropriate performance status based on the future toxicities of the IP/IV regimen, and no prior evidence of medical problems that could significantly worsen during chemotherapy (eg, pre-existing neuropathy).
- Prior to receiving and after receiving each cycle of IP cisplatin, adequate amounts of IV fluids need to be administered in order to prevent renal toxicity. After each cycle has been completed, patients need to be monitored carefully for myelosuppression, dehydration, electrolyte loss, end-organ toxicities (such as renal and hepatic damage), and all other toxicities. Patients often require IV fluids postchemotherapy in the outpatient setting to prevent or help treat dehydration.
- Refer to the original references ([See Discussion](#)) for full toxicity data, doses, schedule, and dose modifications.

[Continued on OV-B 2 of 2](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### PRINCIPLES OF CHEMOTHERAPY (FOR OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCER) (2 of 2)

#### For patients who have recurrent ovarian, fallopian tube, or primary peritoneal cancer:

- Refer to the original references ([See Discussion](#)) for full toxicity data, doses, schedule, and dose modifications.
- Patients should be informed about the following:
  - 1) Availability of clinical trials, including the risks and benefits of various treatments, which will depend on the number of prior lines of chemotherapy the patient has received, and
  - 2) The patient's performance status, end-organ status, and pre-existing toxicities from prior regimens. If appropriate, palliative care should also be discussed as a possible treatment choice. [See NCCN Guidelines for Palliative Care.](#)
- Because of prior platinum exposure, myelosuppression occurs more frequently with any myelotoxic agent given in the recurrent setting.
- With repeat use of either carboplatin and/or cisplatin, patients are at an increased risk of developing a hypersensitivity reaction (also called an allergic reaction) that could be life threatening. Thus, patients should be counseled about the risk that a hypersensitivity reaction may occur, educated about the signs and symptoms of hypersensitivity reactions, treated by medical staff who know how to manage hypersensitivity reactions, and treated in a medical setting where appropriate medical equipment is available in case of an allergic reaction. [See Management of Drug Reactions \(OV-C\).](#)
- Before any chemotherapy drug is given in the recurrent setting, the clinician should be familiar with the drug's metabolism (ie, renal, hepatic) and should make certain that the patient is an appropriate candidate for the drug (eg, that the patient has adequate renal or hepatic function).
- Clinicians should be familiar with toxicity management and appropriate dose reduction.
  
- The schedule, toxicity, and potential benefits of any treatment should be thoroughly discussed with the patient and caregivers. Patient education should also include a discussion of precautions and measures to reduce the severity and duration of complications.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### MANAGEMENT OF DRUG REACTIONS (1 of 7)

#### Overview

- **Virtually all drugs used in oncology have the potential to cause adverse drug reactions while being infused, which can be classified as either infusion or allergic reactions.**<sup>1</sup>
  - Infusion reactions are often characterized by milder symptoms (eg, hot flushing, rash).
  - Hypersensitivity (allergic) reactions are often characterized by more severe symptoms (eg, shortness of breath, generalized hives/itching, changes in blood pressure).
  - Symptoms can overlap, whether caused by infusion or allergic reactions. In addition, patients can have mild allergic reactions or severe infusion reactions.
- **Most adverse drug reactions that occur are mild reactions, but more severe reactions can occur.**<sup>2,3</sup>
  - Anaphylaxis is a rare type of very severe allergic reaction that can occur with the platinum and taxane agents (and others less commonly), can cause cardiovascular collapse, and can be life threatening.<sup>4-6</sup>
  - Drug reactions can occur either during the infusion or following completion of the infusion (and can even occur days later). Reactions can occur with either IV or IP administration.
- **In gynecologic oncology treatment, drugs that more commonly cause adverse reactions include carboplatin, cisplatin, docetaxel, liposomal doxorubicin, oxaliplatin, and paclitaxel.**<sup>1</sup>
  - Adverse reactions associated with taxane drugs (ie, docetaxel, paclitaxel) and biotherapeutic agents tend to be infusion related often attributed to cremophor in paclitaxel and tend to occur during the first few cycles of treatment (although they can be seen during any infusion regardless of how many previous cycles were administered).
  - Adverse reactions associated with platinum drugs (ie, carboplatin, cisplatin), a true allergy, tend to occur following re-exposure to the inciting drug or less commonly at the completion of initial chemotherapy (ie, cycle 6 of a planned 6 treatments).<sup>3</sup>
- **Preparation for a possible drug reaction**
  - Patients and their families need to be counseled about the possibility of a drug reaction, and about the signs and symptoms of an adverse reaction (either infusion or allergic). Patients should be told to report any signs and symptoms of a drug reaction, especially after they have left the clinic.
  - Clinicians and nursing staff should be prepared for the possibility of a drug reaction every time a patient is infused with a drug.
  - Standing orders should be written for immediate intervention in case a severe drug reaction occurs.
  - The treatment area should have appropriate medical equipment in case of a life-threatening reaction.<sup>5</sup>
  - Epinephrine (intramuscular 0.3 mL of 1 mg/mL solution/Epipen) should be used for any patient experiencing hypotension (systolic BP of <90 mm Hg) with or without other symptoms of an allergic/hypersensitivity reaction during or shortly after any chemotherapy drug treatment. In the setting of acute cardiopulmonary arrest, standard resuscitation (ACLS) procedures should be followed.
- **Desensitization refers to a process of rendering the patient less likely to respond to an allergen and can be considered for patients who have had drug reactions.**<sup>1,7-9</sup>
  - Although desensitization is more commonly used after allergic drug reactions, it can also be used after infusion reactions.
  - If a mild reaction has previously occurred to a platinum agent, great caution should be undertaken if desensitization is pursued (see [Allergic Reactions](#)).
- **If a patient has previously had a very severe life-threatening reaction, the implicated drug should not be used again unless under guidance of an allergist or specialist with desensitization experience.**

[Continued on OV-C 2 of 7](#)  
[References on OV-C 3 of 7](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### MANAGEMENT OF DRUG REACTIONS (2 of 7)

#### Infusion Reactions

- Symptoms include: hot flushing, rash, fever, chest tightness, mild blood pressure changes, back pain, and chills.
- Symptoms usually can be treated by decreasing the infusion rate and resolve quickly after stopping the infusion. However, patients who have had mild reactions to carboplatin, cisplatin, or oxaliplatin may develop more serious reactions even when the platinum drug is slowly infused; therefore, consider consultation with an allergist.<sup>10</sup>
- More common with paclitaxel (27% of patients); however, mild reactions can occur with liposomal doxorubicin.<sup>10</sup>
- If an infusion reaction has previously occurred to a taxane:
  - ▶ For mild infusion reactions (eg, flushing, rash, chills), patients may be rechallenged with the taxane if:
    - 1) the patient, physician, and nursing staff are all comfortable with this plan;
    - 2) the patient has been counseled appropriately; and
    - 3) emergency equipment is available in the clinic area.
  - ▶ Typically the taxane infusion can be re-started at a much slower rate, and the rate can be slowly increased as tolerated as per the treating clinician's judgment.<sup>7,11</sup> Note that this slow infusion is different from desensitization.
  - ▶ Many institutions have nursing policies that stipulate how to reinfuse the drug if the patient has had a prior infusion reaction.

#### Allergic Reactions (ie, True Drug Allergies)

- Symptoms include: rash, edema, shortness of breath, syncope or pre-syncope, chest pain, tachycardia, hives/itching, changes in blood pressure, nausea, vomiting, chills, and changes in bowel function. Patients with severe reactions may have the following symptoms: cardiac problems, bronchospasm, blood pressure changes that require treatment, and feeling of impending doom.<sup>11</sup>
- Symptoms continue to persist after stopping infusion and/or after treatment interventions.
- More common with platinum drugs such as carboplatin (16% of patients), cisplatin, and oxaliplatin.<sup>11</sup> Mild reactions can occur with platinum agents.<sup>11</sup>
- Patients who are at higher risk of developing a hypersensitivity (allergic) reaction include those in the following settings:
  - ▶ Re-introduction of the drug after a period of no exposure and following multiple cycles of the drug during the first and subsequent exposures
  - ▶ Intravenous administration of the drug rather than oral or intraperitoneal administration
  - ▶ With allergies to other drugs
  - ▶ Those who have previously had a reaction
- If an allergic reaction has previously occurred:
  - ▶ Consider consultation with an allergist (or qualified medical or gynecologic oncologist) and skin testing for patients who have experienced a platinum reaction (eg, carboplatin-hypersensitivity reaction).<sup>11-13</sup>
  - ▶ Patients who have had mild reactions may develop more serious reactions even when the platinum drug is slowly infused.<sup>11</sup> The desensitization treatment of these patients should be managed by a physician with expertise and experience in platinum desensitization.
  - ▶ For very severe life-threatening reactions (ie, anaphylaxis), the implicated drug should not be used again unless under guidance of an allergist or specialist with desensitization experience.
  - ▶ For more severe reactions--such as those involving blood pressure changes, dyspnea, tachycardia, widespread urticaria, hypoxia--the treating clinician should consult an allergist prior to rechallenge.
  - ▶ If it is appropriate to give the drug again, patients should be desensitized prior to resuming chemotherapy even if the symptoms have resolved. Patients must be desensitized with each infusion if they previously had a drug reaction.<sup>7-9</sup>

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[References on OV-C 3 of 7](#)



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### MANAGEMENT OF DRUG REACTIONS (3 of 7)

#### REFERENCES

- <sup>1</sup>Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. *J Allergy Clin Immunol* 2008;122:574-580.
- <sup>2</sup>Dizon DS, Sabbatini PJ, Aghajanian C, et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. *Gynecol Oncol* 2002;84:378-382.
- <sup>3</sup>Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. *J Clin Oncol* 1999;17:1141-1145.
- <sup>4</sup>Manivannan V, Decker WW, Stead LG, et al. Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. *Int J Emerg Med* 2009;2:3-5.
- <sup>5</sup>Oswalt ML, Kemp SF. Anaphylaxis: office management and prevention. *Immunol Allergy Clin North Am* 2007;27:177-191.
- <sup>6</sup>Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. *Ann Emerg Med* 2006;47:373-380.
- <sup>7</sup>Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. *Gynecol Oncol* 2005;99:393-397.
- <sup>8</sup>Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: A 6-hour 12 step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. *Gynecol Oncol* 2004;95:370-376.
- <sup>9</sup>Markman M, Hsieh F, Zanotti K, et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions. *J Cancer Research Clin Oncol* 2004;130:25-28.
- <sup>10</sup>Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. *Cancer Invest* 2001;19:424-436.
- <sup>11</sup>Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. *Oncologist* 2007;12:601-609.
- <sup>12</sup>Markman M, Zanotti K, Peterson G, et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. *J Clin Oncol* 2003;21:4611-4614.
- <sup>13</sup>Zanotti KM, Rybicki LA, Kennedy AW, et al. Carboplatin skin testing: A skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. *J Clin Oncol* 2001;19:3126-3129.

[See Drug Reaction to Platinum Agents on OV-C 4 of 7](#)

[See Drug Reaction to Taxane, Liposomal Doxorubicin, or Biotherapeutic Agents on OV-C 6 of 7](#)

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### MANAGEMENT OF DRUG REACTIONS (4 of 7)



<sup>1</sup> Most mild reactions are infusion reactions and more commonly are caused by taxanes (ie, docetaxel, paclitaxel), but can also occur with platinum agents (ie, carboplatin, cisplatin).

<sup>2</sup> Most severe reactions are allergic reactions and more commonly are caused by platinum agents.

<sup>3</sup> Antihistamine (eg, diphenhydramine or hydroxyzine); H2 blockers (eg, cimetidine, famotidine); corticosteroids (eg, methylprednisolone, hydrocortisone, dexamethasone).

<sup>4</sup> In the setting of acute cardiopulmonary arrest, standard resuscitation (ACLS) procedures should be followed.

[See Drug Reaction to Taxane, Liposomal Doxorubicin, or Biotherapeutic Agents on OV-C 6 of 7](#)

<sup>5</sup> Mild reactions can progress to severe reactions by re-exposure. An allergy consultation may provide skin testing and evaluate sensitization and the risk for further, more severe reactions.

<sup>6</sup> Referral to academic center with expertise in desensitization is preferred.

<sup>7</sup> Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. *J Allergy Clin Immunol* 2008;122:574-580.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### MANAGEMENT OF DRUG REACTIONS (5 of 7)

#### DRUG REACTION TO PLATINUM AGENTS



<sup>1</sup>Most mild reactions are infusion reactions and more commonly are caused by taxanes (ie, docetaxel, paclitaxel), but can also occur with platinum agents (ie, carboplatin, cisplatin).

<sup>2</sup>Most severe reactions are allergic reactions and more commonly are caused by platinum agents.

<sup>3</sup>Antihistamine (eg, diphenhydramine or hydroxyzine); H2 blockers (eg, cimetidine, famotidine); corticosteroids (eg, methylprednisolone, hydrocortisone, dexamethasone).

<sup>4</sup>In the setting of acute cardiopulmonary arrest, standard resuscitation (ACLS) procedures should be followed.

[See Drug Reaction to Taxane, Liposomal Doxorubicin, or Biotherapeutic Agents on OV-C 6 of 7](#)

<sup>6</sup>Referral to academic center with expertise in desensitization is preferred.

<sup>7</sup>Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. *J Allergy Clin Immunol* 2008;122:574-580.

<sup>8</sup>For both taxanes and platinum analogues, it is preferred that anyone with a life-threatening reaction be evaluated and referred to an academic center if the drug is still considered first line.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### DRUG REACTION TO TAXANE, LIPOSOMAL DOXORUBICIN, OR BIOTHERAPEUTIC AGENTS

### MANAGEMENT OF DRUG REACTIONS (6 of 7)

IV or IP  
drug reaction  
to taxane,  
liposomal  
doxorubicin,  
or  
biotherapeutic  
agents

#### REACTION

#### MANAGEMENT/TREATMENT<sup>3</sup>

**Mild reaction<sup>1</sup>**  
(hot flushing, rash, pruritus,  
pain in chest/abdomen/  
pelvis/back)

- Stop infusion
  - ▶ Symptoms often resolve quickly after stopping infusion
- Administer antihistamine to treat symptoms

- If staff agree and vital signs remain stable, rechallenge with drug at slower infusion rate<sup>9</sup>
  - ▶ Administer premedication with antihistamine, corticosteroids, H2 blockers

- If repeat mild reaction, then do not rechallenge/ readminister
- Potential candidate for desensitization<sup>7,9</sup> with each infusion

**Severe reaction<sup>2</sup>**  
(shortness of breath, changes in blood pressure requiring treatment, dyspnea, GI symptoms [nausea, vomiting]), pain in chest/abdomen/pelvis/back, feeling of impending doom/anxiety/something wrong)

[See OV-C 7 of 7](#)

**Life-threatening reaction<sup>2</sup> (ie, anaphylaxis)**  
(acute onset, generalized hives, respiratory compromise, severe hypotension, GI symptoms [nausea, vomiting]), pain in chest/abdomen/pelvis/back, feeling of impending doom/anxiety/something wrong)

[See OV-C 7 of 7](#)

[See Drug Reaction to Platinum Agents on OV-C 4 of 7](#)

<sup>1</sup>Most mild reactions are infusion reactions and more commonly are caused by taxanes (ie, docetaxel, paclitaxel), but can also occur with platinum agents (ie, carboplatin, cisplatin).

<sup>2</sup>Most severe reactions are allergic reactions and more commonly are caused by platinum agents.

<sup>3</sup>**Antihistamine** (eg, diphenhydramine or hydroxyzine); **H2 blockers** (eg, cimetidine, famotidine); **corticosteroids** (eg, methylprednisolone, hydrocortisone, dexamethasone).

<sup>7</sup>Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. *J Allergy Clin Immunol* 2008;122:574-580.

<sup>9</sup>Consider switching to docetaxel; however, there are no data to support switching taxanes. Cross reactions have occurred and have been life-threatening. Some reactions to paclitaxel may occur because of the diluent.

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.





# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer



<sup>1</sup> Most mild reactions are infusion reactions and more commonly are caused by taxanes (ie, docetaxel, paclitaxel), but can also occur with platinum agents (ie, carboplatin, cisplatin).

<sup>2</sup> Most severe reactions are allergic reactions and more commonly are caused by platinum agents.

<sup>3</sup> Antihistamine (eg, diphenhydramine or hydroxyzine); H2 blockers (eg, cimetidine, famotidine); corticosteroids (eg, methylprednisolone, hydrocortisone, dexamethasone).

<sup>4</sup> In the setting of acute cardiopulmonary arrest, standard resuscitation (ACLS) procedures should be followed.

<sup>6</sup> Referral to academic center with expertise in desensitization is preferred.

[See Drug Reaction to Platinum Agents on OV-C 4 of 7](#)

<sup>7</sup> Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. *J Allergy Clin Immunol* 2008;122:574-580.

<sup>8</sup> For both taxanes and platinum analogues, it is preferred that anyone with a life-threatening reaction be evaluated and referred to an academic center if the drug is still considered first line.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### PRIMARY CHEMOTHERAPY/PRIMARY ADJUVANT THERAPY REGIMENS FOR STAGE II-IV<sup>1</sup>

1. Paclitaxel 135 mg/m<sup>2</sup> IV continuous infusion over 3 or 24 h<sup>2</sup> Day 1; cisplatin 75-100 mg/m<sup>2</sup> IP, Day 2 after IV paclitaxel; paclitaxel 60 mg/m<sup>2</sup> IP Day 8. Repeat every 3 weeks x 6 cycles. (category 1)
2. Paclitaxel 175 mg/m<sup>2</sup> IV over 3 hours followed by carboplatin<sup>3</sup> AUC 5- 7.5 IV over 1 hour Day 1. Repeat every 3 weeks x 6 cycles. (category 1)
3. Docetaxel 60-75 mg/m<sup>2</sup> IV over 1 hour followed by carboplatin<sup>3</sup> AUC 5 - 6 IV over 1 hour Day 1. Repeat every 3 weeks x 6 cycles. (category 1)
4. Dose-dense paclitaxel 80 mg/m<sup>2</sup> IV over 1 hour Days 1, 8, and 15 and carboplatin<sup>3</sup> AUC 6 IV over 1 hour Day 1. Repeat every 3 weeks x 6 cycles. (category 1)
5. Bevacizumab-containing regimens per ICON-7 and GOG-218:  
Paclitaxel 175 mg/m<sup>2</sup> IV over 3 hours, carboplatin<sup>3</sup> AUC 6 IV over 1 hour, and bevacizumab 7.5 mg/kg IV over 30-90 minutes Day 1. Repeat every 3 weeks x 5-6 cycles. Continue bevacizumab for up to 12 additional cycles. (category 3)  
or  
Paclitaxel 175 mg/m<sup>2</sup> IV over 3 hours and carboplatin<sup>3</sup> AUC 6 IV over 1 hour Day 1. Repeat every 3 weeks x 6 cycles. Starting Day 1 of cycle 2, give bevacizumab 15 mg/kg IV over 30-90 minutes every 3 weeks for up to 22 cycles. (category 3)

[See Management \(OV-3\)](#)

<sup>1</sup> See [Discussion](#) for references.

<sup>2</sup> The published randomized trial regimen used IV continuous infusion paclitaxel over 24 h.

<sup>3</sup> Due to changes in creatinine methodology, changes regarding carboplatin dosing can be considered. See [FDA carboplatin dosing statement](#).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### ACCEPTABLE RECURRENCE THERAPIES (1 of 2)<sup>†</sup>

| Agents                                 | Cytotoxic Therapy   | Hormonal Therapy | Targeted Therapy | Radiation Therapy |                           |                  |                  |            |            |            |             |           |  |             |  |   |  |  |
|--|---|------------------|------------------|-------------------|---------------------------|------------------|------------------|------------|------------|------------|-------------|-----------|--|-------------|--|---|--|--|
| <b>Preferred Agents</b>                | <p><b>Combination if platinum sensitive</b> ‡ ¶</p> <p>Carboplatin/paclitaxel (category 1)<sup>1</sup></p> <p>Carboplatin/weekly paclitaxel<sup>2</sup></p> <p>Carboplatin/docetaxel<sup>3,4</sup></p> <p>Carboplatin/gemcitabine<sup>5</sup></p> <p>Carboplatin/gemcitabine/bevacizumab* (category 2B)<sup>6</sup></p> <p>Carboplatin/liposomal doxorubicin<sup>7</sup></p> <p>Cisplatin/gemcitabine<sup>8</sup></p> <p><b>Single-agent if platinum sensitive</b></p> <p>Carboplatin<sup>6</sup></p> <p>Cisplatin<sup>6</sup></p> <p><b>Single-agent non-platinum-based if platinum resistant</b></p> <p>Docetaxel<sup>9</sup></p> <p>Etoposide, oral<sup>10</sup></p> <p>Gemcitabine<sup>11,12</sup></p> <p>Liposomal doxorubicin<sup>11,12</sup></p> <p>Paclitaxel, weekly<sup>13</sup></p> <p>Topotecan<sup>14,15</sup></p> |                  | Bevacizumab      |                   |                           |                  |                  |            |            |            |             |           |  |             |  |   |  |  |
| <b>Other Potentially Active Agents</b> | <p><b>Single agents</b><sup>16</sup></p> <table border="0"> <tr> <td>Altretamine</td> <td>Paclitaxel</td> </tr> <tr> <td>Capecitabine</td> <td>Paclitaxel, albumin bound</td> </tr> <tr> <td>Cyclophosphamide</td> <td>(nab-paclitaxel)</td> </tr> <tr> <td>Ifosfamide</td> <td>Pemetrexed</td> </tr> <tr> <td>Irinotecan</td> <td>Vinorelbine</td> </tr> <tr> <td>Melphalan</td> <td></td> </tr> <tr> <td>Oxaliplatin</td> <td></td> </tr> </table>  | Altretamine      | Paclitaxel       | Capecitabine      | Paclitaxel, albumin bound | Cyclophosphamide | (nab-paclitaxel) | Ifosfamide | Pemetrexed | Irinotecan | Vinorelbine | Melphalan |  | Oxaliplatin |  | <p>Anastrozole</p> <p>Letrozole</p> <p>Leuprolide acetate</p> <p>Megestrol acetate</p> <p>Tamoxifen</p> |  | Palliative localized radiation therapy |
| Altretamine                            | Paclitaxel  |                  |                  |                   |                           |                  |                  |            |            |            |             |           |  |             |  |   |  |  |
| Capecitabine                           | Paclitaxel, albumin bound   |                  |                  |                   |                           |                  |                  |            |            |            |             |           |  |             |  |   |  |  |
| Cyclophosphamide                       | (nab-paclitaxel)  |                  |                  |                   |                           |                  |                  |            |            |            |             |           |  |             |  |   |  |  |
| Ifosfamide                             | Pemetrexed  |                  |                  |                   |                           |                  |                  |            |            |            |             |           |  |             |  |   |  |  |
| Irinotecan                             | Vinorelbine   |                  |                  |                   |                           |                  |                  |            |            |            |             |           |  |             |  |   |  |  |
| Melphalan                              |   |                  |                  |                   |                           |                  |                  |            |            |            |             |           |  |             |  |   |  |  |
| Oxaliplatin                            |   |                  |                  |                   |                           |                  |                  |            |            |            |             |           |  |             |  |   |  |  |

<sup>†</sup>Patients who progress on two consecutive therapy regimens without evidence of clinical benefits have diminished likelihood of benefitting from additional therapy. (Griffiths RW, et al. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gyn Ca 2011;21:58-65.) Decisions to offer clinical trials, supportive care, or additional therapy should be made on a highly individual basis.

<sup>‡</sup>In general, the Panel would recommend combination regimens based on randomized trial data, especially in first relapses.

\*In patients who have not previously received bevacizumab.

¶Platinum-based combination therapy should be considered for platinum-sensitive recurrences.

[See References \(OV-E 2 of 2\)](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer

### ACCEPTABLE RECURRENCE THERAPIES (2 of 2)

#### REFERENCES

- <sup>1</sup>Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet* 2003;361:2099-2106.
- <sup>2</sup>Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet* 2009;374:1331-1338.
- <sup>3</sup>Strauss HG, Henze A, Teichmann A, et al. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. *Gynecol Oncol* 2007;104:612-616.
- <sup>4</sup>Kushner DM, Connor JP, Sanchez F, et al. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. *Gynecol Oncol* 2007;105:358-364.
- <sup>5</sup>Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. *J Clin Oncol* 2006;24:4699-4707.
- <sup>6</sup>Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *J Clin Oncol* 2012;30:2039-2045.
- <sup>7</sup>Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. *J Clin Oncol* 2010;28:3323-3329.
- <sup>8</sup>Rose PG. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. *Int J Gynecol Cancer* 2005;15:18-22.
- <sup>9</sup>Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2003;88:130-135.
- <sup>10</sup>Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 1998;16:405-410.
- <sup>11</sup>Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. *J Clin Oncol* 2007;25:2811-2818.
- <sup>12</sup>Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. *J Clin Oncol* 2008;26:890-896.
- <sup>13</sup>Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80 mg/m<sup>2</sup>) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. *Gynecol Oncol* 2006;101:436-440.
- <sup>14</sup>Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. *Gynecol Oncol* 2004;95:1-8.
- <sup>15</sup>Sehouli J, Stengel D, Harter P, et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: A randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. *J Clin Oncol* 2011;29:242-248.
- <sup>16</sup>See Discussion for references.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 2.2013

## Less Common Ovarian Histopathologies

### CLINICAL PRESENTATION

### WORKUP

### DIAGNOSIS




<sup>a</sup>[See Sex Cord-Stromal Tumors - WHO Histologic Classification \(LCOH-A\).](#)

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Malignant Germ Cell Tumors




<sup>b</sup>Standard recommendation includes a patient evaluation by a gynecologic oncologist.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Malignant Germ Cell Tumors



<sup>c</sup>For select patients with stage IB-III dysgerminoma for whom minimizing toxicity is critical, 3 courses of etoposide/carboplatin can be used (3 courses of carboplatin 400 mg/m<sup>2</sup> on day 1 plus etoposide 120 mg/m<sup>2</sup> on days 1, 2, and 3 every 4 weeks).

<sup>d</sup>BEP (bleomycin, 30 units per week; etoposide, 100 mg/m<sup>2</sup>/d daily for days 1-5; cisplatin 20 mg/m<sup>2</sup>/d daily for days 1-5) for 3-4 cycles (category 2B for 3 versus 4 cycles). Recommend pulmonary function tests if considering bleomycin.

<sup>e</sup>[See LCOH-1 for markers.](#)

<sup>f</sup>[See Acceptable Recurrence Therapies \(LCOH-C\).](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013


## Malignant Sex Cord-Stromal Tumors

**CLINICAL  
PRESENTATION**

**TREATMENT**

**RECURRENT  
DISEASE**

**RECURRENCE  
THERAPY**



<sup>a</sup>See Sex Cord-Stromal Tumors - WHO Histologic Classification (LCOH-A).

<sup>f</sup>See Acceptable Recurrence Therapies (LCOH-C).

<sup>g</sup>Lymphadenectomy may be omitted.

<sup>h</sup>See Principles of Primary Surgery (OV-A).

<sup>i</sup>Inhibin levels can be followed if initially elevated for granulosa cell tumors (category 2B).

<sup>j</sup>Malignant germ cell regimens (See LCOH-3) or paclitaxel/carboplatin regimens are preferred.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.






# NCCN Guidelines Version 2.2013

## Carcinosarcoma (Malignant Mixed Müllerian Tumors)

### CLINICAL PRESENTATION

### TREATMENT



<sup>h</sup>[See Principles of Primary Surgery \(OV-A\).](#)

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**SEX CORD-STROMAL TUMORS - WHO HISTOLOGIC CLASSIFICATION<sup>1</sup>**

- Sex cord-stromal tumors are a heterogenous group of very rare tumors from benign to aggressive, and each histology has a range of often well differentiated to undifferentiated. Therefore, it should be determined whether a patient has a malignant or benign sex cord-stromal tumor.
- Treatment decisions and the decision whether to preserve fertility must be individualized based on the patient's specific tumor features.

| <u>WHO Histologic Classification</u>                            | <u>Pathology</u>                     |
|---|--------------------------------------|
| <b>Granulosa cell tumors</b>                                    |                                      |
| <b>Adult</b>  | <b>Malignant</b>                     |
| <b>Juvenile</b>   | <b>Malignant</b>                     |
| <b>Thecoma</b>  |                                      |
| <b>Thecomas typical</b>   | <b>Benign</b>                        |
| <b>Thecomas, luteinized</b>                                     | <b>Malignant potential</b>           |
| <b>Thecoma with increased mitotic figures</b>                   | <b>Malignant potential</b>           |
| <b>Fibroma</b>  |                                      |
| <b>Cellular fibroma</b>   | <b>Malignant potential</b>           |
| <b>Cellular fibroma with increased mitotic figures</b>          | <b>Malignant potential</b>           |
| <b>Fibrosarcoma</b>   | <b>Malignant</b>                     |
| <b>Stromal tumor with minor sex cord elements</b>               | <b>Benign</b>                        |
| <b>Sclerosing stromal tumor</b>                                 | <b>Benign</b>                        |
| <b>Signet ring stromal tumors</b>                               | <b>Benign</b>                        |
| <b>Unclassified</b>   | <b>Malignant potential</b>           |
| <b>Sertoli-Leydig cell tumors</b>                               |                                      |
| <b>Well differentiated</b>                                      | <b>Malignant potential</b>           |
| <b>Intermediate differentiation</b>                             | <b>Malignant</b>                     |
| <b>Poorly differentiated</b>                                    | <b>Malignant</b>                     |
| <b>Sertoli-Leydig tumors with heterologous elements</b>         | <b>Malignant</b>                     |
| <b>Sertoli cell tumors</b>                                      | <b>Malignant potential</b>           |
| <b>Leydig cell tumors</b>                                       | <b>Benign</b>                        |
| <b>Stromal-Leydig cell tumors</b>                               | <b>Benign</b>                        |
| <b>Sex cord tumors with annular tubules (SCTAT)</b>             | <b>Malignant</b>                     |
| <b>Microscopic SCTAT associated with Peutz-Jeghers syndrome</b> | <b>Benign</b>                        |
| <b>Gynandroblastoma</b>   | <b>Malignant/Malignant potential</b> |
| <b>Unclassified sex cord stromal tumors</b>                     | <b>Malignant potential</b>           |
| <b>Steroid cell tumors</b>                                      | <b>Malignant</b>                     |

<sup>1</sup>Adapted from Tavassoli FA, Devilee P (Eds): WHO Classification of Tumours, Pathology and Genetics: Tumours of the Breast and Female Genital Organs. IARC, Lyon, 2003.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2013

## Malignant Sex Cord-Stromal Tumors

### SURVEILLANCE FOR GERM CELL AND SEX CORD-STROMAL TUMORS<sup>1</sup>

|                                     | Years   |   |  |  |  |
|-------------------------------------|---|---|--|--|--|
|                                     | <1  | 1-2   | 2-3                                      | 3-5                                      | >5                                       |
| <b><u>Physical exam</u></b>         |   |   |  |  |  |
| <b>Germ cell tumors</b>             | Every 2-4 mo  | Every 2-4 mo  | Yearly                                   | Yearly                                   | Yearly                                   |
| <b>Sex cord-stromal tumors</b>      | Every 2-4 mo  | Every 2-4 mo  | Every 6 mo                               | Every 6 mo                               | Every 6 mo                               |
| <b><u>Serum tumor markers**</u></b> |   |   |  |  |  |
| <b>Germ cell tumors</b>             | Every 2-4 mo  | Every 2-4 mo  | Not indicated                            | Not indicated                            | Not indicated                            |
| <b>Sex cord-stromal tumors</b>      | Every 2-4 mo  | Every 2-4 mo  | Every 6 mo                               | Every 6 mo                               | Every 6 mo                               |
| <b><u>Radiographic imaging*</u></b> |   |   |  |  |  |
| <b>Germ cell tumors</b>             | Not indicated unless markers normal at initial presentation | Not indicated unless markers normal at initial presentation | Not indicated                            | Not indicated                            | Not indicated                            |
| <b>Sex cord-stromal tumors</b>      | Insufficient data to support routine use                    | Insufficient data to support routine use                    | Insufficient data to support routine use | Insufficient data to support routine use | Insufficient data to support routine use |
| <b><u>Recurrence suspected</u></b>  | CT scan and tumor markers**                                 | CT scan and tumor markers**                                 | CT scan and tumor markers**              | CT scan and tumor markers**              | CT scan and tumor markers**              |

\*Chest x-ray, CT, MRI

\*\*See [LCOH-1](#) for markers.

<sup>1</sup>With permission, Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011;204:466-478.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



### ACCEPTABLE RECURRENCE THERAPIES

#### **MALIGNANT GERM CELL TUMORS**<sup>1</sup>

High-dose chemotherapy<sup>1,2</sup>

Cisplatin/etoposide

Docetaxel

Docetaxel/carboplatin

Paclitaxel

Paclitaxel/ifosfamide

Paclitaxel/carboplatin

Paclitaxel/gemcitabine

VIP (etoposide, ifosfamide, cisplatin)

VeIP (vinblastine, ifosfamide, cisplatin)

VAC (vincristine, dactinomycin, cyclophosphamide)

TIP (paclitaxel, ifosfamide, cisplatin)

Radiation therapy

Supportive care only

#### **MALIGNANT SEX CORD-STROMAL TUMORS**<sup>3</sup>

Aromatase inhibitors (anastrozole, letrozole)

Bevacizumab may be considered for granulosa cell tumors

Leuprolide may be used as hormonal therapy for granulosa cell tumors

Docetaxel

Paclitaxel

Paclitaxel/ifosfamide

Paclitaxel/carboplatin

Tamoxifen

VAC

Radiation therapy

Supportive care only

<sup>1</sup>Patients with potentially curable recurrent germ cell disease should be referred to a tertiary care institution for potentially curative therapy.

<sup>2</sup>High-dose chemotherapy regimens vary among institutions.

<sup>3</sup>[See Sex Cord-Stromal Tumors - WHO Histologic Classification \(LCOH-A\).](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



## Staging

**Table 1**

**American Joint Committee on Cancer (AJCC)**

**TNM and FIGO Staging System for Ovarian and Primary Peritoneal Cancer (7th ed., 2010)**

### **Primary Tumor (T)**

#### **TNM FIGO**

|            |            |   |
|------------|------------|---|
| <b>TX</b>  |            | Primary tumor cannot be assessed  |
| <b>T0</b>  |            | No evidence of primary tumor  |
| <b>T1</b>  | <b>I</b>   | Tumor limited to ovaries (one or both)  |
| <b>T1a</b> | <b>IA</b>  | Tumor limited to one ovary; capsule intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings                                 |
| <b>T1b</b> | <b>IB</b>  | Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings                             |
| <b>T1c</b> | <b>IC</b>  | Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings |
| <b>T2</b>  | <b>II</b>  | Tumor involves one or both ovaries with pelvic extension  |
| <b>T2a</b> | <b>IIA</b> | Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings  |
| <b>T2b</b> | <b>IIB</b> | Extension to and/or implants on other pelvic tissues. No malignant cells in ascites or peritoneal washings  |
| <b>T2c</b> | <b>IIC</b> | Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washings  |

#### **TNM FIGO**

|            |             |  |
|------------|-------------|--|
| <b>T3</b>  | <b>III</b>  | Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis     |
| <b>T3a</b> | <b>IIIA</b> | Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor)   |
| <b>T3b</b> | <b>IIIB</b> | Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension                             |
| <b>T3c</b> | <b>IIIC</b> | Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis |

### **Regional Lymph Nodes (N)**

|           |             |   |
|-----------|-------------|---|
| <b>NX</b> |             | Regional lymph nodes cannot be assessed |
| <b>N0</b> |             | No regional lymph node metastasis       |
| <b>N1</b> | <b>IIIC</b> | Regional lymph node metastasis          |

### **Distant Metastasis (M)**

|           |           |   |
|-----------|-----------|---|
| <b>M0</b> |           | No distant metastasis                               |
| <b>M1</b> | <b>IV</b> | Distant metastasis (excludes peritoneal metastasis) |

Note: Liver capsule metastasis is T3/stage III; liver parenchymal metastasis, M1/stage IV. Pleural effusion must have positive cytology for M1/stage IV.

[\*\*Continued\*\*](#)



## Staging

### *Table 1 (Continued)*

#### American Joint Committee on Cancer (AJCC)

#### TNM and FIGO Staging System for Ovarian and Primary Peritoneal Cancer (7th ed., 2010)

##### Stage Grouping

|                   |       |       |    |
|-------------------|-------|-------|----|
| <b>Stage 1</b>    | T1    | N0    | M0 |
| <b>Stage IA</b>   | T1a   | N0    | M0 |
| <b>Stage IB</b>   | T1b   | N0    | M0 |
| <b>Stage IC</b>   | T1c   | N0    | M0 |
| <b>Stage II</b>   | T2    | N0    | M0 |
| <b>Stage IIA</b>  | T2a   | N0    | M0 |
| <b>Stage IIB</b>  | T2b   | N0    | M0 |
| <b>Stage IIC</b>  | T2c   | N0    | M0 |
| <b>Stage III</b>  | T3    | N0    | M0 |
| <b>Stage IIIA</b> | T3a   | N0    | M0 |
| <b>Stage IIIB</b> | T3b   | N0    | M0 |
| <b>Stage IIIC</b> | T3c   | N0    | M0 |
|                   | Any T | N1    | M0 |
| <b>Stage IV</b>   | Any T | Any N | M1 |

The staging system for ovarian and primary peritoneal cancer is also used for malignant germ cell tumors, malignant sex cord-stromal tumors, and carcinosarcoma (malignant mixed Müllerian tumors).

Note: For histologic grade and histopathologic type, see AJCC Staging Manual.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.cancerstaging.net](http://www.cancerstaging.net).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.



## Staging

**Table 2****American Joint Committee on Cancer (AJCC)**  
**TNM and FIGO Staging System for Fallopian Tube Cancer (7th ed., 2010)****Primary Tumor (T)****TNM FIGO**

|             |            |   |
|-------------|------------|---|
| <b>TX</b>   |            | Primary tumor cannot be assessed  |
| <b>T0</b>   |            | No evidence of primary tumor  |
| <b>Tis*</b> |            | Carcinoma in situ (limited to tubal mucosa)   |
| <b>T1</b>   | <b>I</b>   | Tumor limited to the fallopian tube(s)  |
| <b>T1a</b>  | <b>IA</b>  | Tumor limited to one tube, without penetrating the serosal surface; no ascites  |
| <b>T1b</b>  | <b>IB</b>  | Tumor limited to both tubes, without penetrating the serosal surface; no ascites  |
| <b>T1c</b>  | <b>IC</b>  | Tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings |
| <b>T2</b>   | <b>II</b>  | Tumor involves one or both fallopian tubes with pelvic extension  |
| <b>T2a</b>  | <b>IIA</b> | Extension and/or metastasis to the uterus and/or ovaries  |
| <b>T2b</b>  | <b>IIB</b> | Extension to other pelvic structures  |
| <b>T2c</b>  | <b>IIC</b> | Pelvic extension with malignant cells in ascites or peritoneal washings   |

**TNM FIGO**

|            |             |   |
|------------|-------------|---|
| <b>T3</b>  | <b>III</b>  | Tumor involves one or both fallopian tubes, with peritoneal implants outside the pelvis |
| <b>T3a</b> | <b>IIIA</b> | Microscopic peritoneal metastasis outside the pelvis                                    |
| <b>T3b</b> | <b>IIIB</b> | Macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension |
| <b>T3c</b> | <b>IIIC</b> | Peritoneal metastasis outside the pelvis and more than 2 cm in diameter                 |

**Regional Lymph Nodes (N)**

|           |             |   |
|-----------|-------------|---|
| <b>NX</b> |             | Regional lymph nodes cannot be assessed |
| <b>N0</b> |             | No regional lymph node metastasis       |
| <b>N1</b> | <b>IIIC</b> | Regional lymph node metastasis          |

**Distant Metastasis (M)**

|           |           |   |
|-----------|-----------|---|
| <b>M0</b> |           | No distant metastasis   |
| <b>M1</b> | <b>IV</b> | Distant metastasis (excludes metastasis within the peritoneal cavity) |

\* Note: FIGO no longer includes stage 0 (Tis)

Note: Liver capsule metastasis is T3/stage III; liver parenchymal metastasis, M1/stage IV. Pleural effusion must have positive cytology for M1/stage IV.

**Continued**



## Staging

**Table 2 (Continued)**

**American Joint Committee on Cancer (AJCC)**  
**TNM and FIGO Staging System for Fallopian Tube Cancer (7th ed., 2010)**

### Stage Grouping

|                   |       |       |    |
|-------------------|-------|-------|----|
| <b>Stage 0*</b>   | Tis   | N0    | M0 |
| <b>Stage 1</b>    | T1    | N0    | M0 |
| <b>Stage IA</b>   | T1a   | N0    | M0 |
| <b>Stage IB</b>   | T1b   | N0    | M0 |
| <b>Stage IC</b>   | T1c   | N0    | M0 |
| <b>Stage II</b>   | T2    | N0    | M0 |
| <b>Stage IIA</b>  | T2a   | N0    | M0 |
| <b>Stage IIB</b>  | T2b   | N0    | M0 |
| <b>Stage IIC</b>  | T2c   | N0    | M0 |
| <b>Stage III</b>  | T3    | N0    | M0 |
| <b>Stage IIIA</b> | T3a   | N0    | M0 |
| <b>Stage IIIB</b> | T3b   | N0    | M0 |
| <b>Stage IIIC</b> | T3c   | N0    | M0 |
|                   | Any T | N1    | M0 |
| <b>Stage IV</b>   | Any T | Any N | M1 |

\*Note: FIGO no longer includes stage 0 (Tis)

Note: For histologic grade and histopathologic type, see AJCC Staging Manual.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media LLC (SBM). (For complete information and data supporting the staging tables, visit [www.cancerstaging.net](http://www.cancerstaging.net).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.



## Discussion

### NCCN Categories of Evidence and Consensus

**Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

**All recommendations are category 2A unless otherwise noted.**

## Table of Contents

|                                     |      |
|-------------------------------------|------|
| Overview .....                      | MS-2 |
| Screening .....                     | MS-2 |
| Staging .....                       | MS-4 |
| Caveat .....                        | MS-4 |
| Epithelial Ovarian Cancer .....     | MS-4 |
| Recommended Workup .....            | MS-4 |
| Undiagnosed Pelvic Mass .....       | MS-4 |
| Prior Diagnosis of Malignancy ..... | MS-5 |
| Primary Treatment .....             | MS-5 |

|  |       |
|--|-------|
| Incompletely Staged Patients .....                                   | MS-7  |
| Chemotherapy .....   | MS-7  |
| Anti-Angiogenesis Agents .....                                       | MS-9  |
| Number of Chemotherapy Cycles and Agents .....                       | MS-10 |
| Radiation Therapy .....  | MS-11 |
| Recommendations After Primary Treatment .....                        | MS-11 |
| Follow-up Recommendations .....                                      | MS-12 |
| Management of an Increasing CA-125 Level .....                       | MS-12 |
| Recurrent Disease .....  | MS-13 |
| Acceptable Recurrence Modalities .....                               | MS-13 |
| Borderline Epithelial Ovarian Cancer (Low Malignant Potential) ..... | MS-15 |
| Diagnosis .....  | MS-15 |
| Treatment .....  | MS-16 |
| Follow-up .....  | MS-16 |
| Less Common Ovarian Histopathologies .....                           | MS-17 |
| Overview .....   | MS-17 |
| Recommended Workup .....   | MS-17 |
| Malignant Germ Cell Tumors .....                                     | MS-17 |
| Malignant Sex Cord-Stromal Tumors .....                              | MS-19 |
| Carcinosarcoma (Malignant Mixed Müllerian Tumors) .....              | MS-19 |
| Recommended Readings .....   | MS-20 |
| References .....   | MS-21 |

### Overview

Ovarian neoplasms consist of several histopathologic entities; treatment depends on the specific tumor type. Epithelial ovarian cancer comprises the majority of malignant ovarian neoplasms (about 90%);<sup>1-3</sup> however, other less common pathologic subtypes should be mentioned in guidelines describing treatment recommendations. These NCCN Guidelines discuss epithelial ovarian cancer (including borderline or low malignant potential [LMP]) and less common histopathologies, including malignant germ cell neoplasms, carcinosarcomas (malignant mixed Müllerian tumors [MMMT] of the ovary), and sex cord-stromal tumors. The guidelines also discuss Fallopian tube cancer and primary peritoneal cancer, which are less common neoplasms that are managed in a similar manner to epithelial ovarian cancer. However, the less common histologies of ovarian cancer are managed differently. These NCCN Guidelines also include sections on *Principles of Chemotherapy* (including *Acceptable Recurrence Therapies*), *Principles of Primary Surgery*, and *Management of Drug Reactions*. The *Updates* section in the algorithm briefly describes the new changes for 2013 (see the NCCN Guidelines for Ovarian Cancer).

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. In 2013, it is estimated that 22,240 new diagnoses and 14,030 deaths from this neoplasm will occur in the United States; less than 40% of women with ovarian cancer are cured.<sup>4</sup> The incidence of ovarian cancer increases with age and is most prevalent in the sixth and seventh decades of life.<sup>3</sup> The median age at the time of diagnosis is 63 years, and more than 70% of patients present with advanced disease.<sup>5,6</sup>

Epidemiologic studies have identified risk factors in the etiology of ovarian cancer.<sup>3,7</sup> A 30% to 60% decreased risk for cancer is associated with younger age at pregnancy and first birth ( $\leq 25$  years), the use of oral contraceptives, and/or breast-feeding.<sup>5</sup> Conversely, nulliparity or older age ( $> 35$  years) at pregnancy and first birth confers an increased risk for cancer. Recent data suggest that hormone therapy and pelvic inflammatory disease may increase the risk for ovarian cancer.<sup>8-10</sup> The risk for borderline ovarian cancer may be increased after ovarian stimulation for in vitro fertilization.<sup>11,12</sup> Obesity does not appear to be associated with the most aggressive types of ovarian cancer.<sup>13</sup>

Family history (primarily patients having 2 or more first-degree relatives with ovarian cancer)—including linkage with *BRCA1* and *BRCA2* genotypes or families affected by Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC] syndrome)—is associated with early-onset disease.<sup>14-21</sup> However, these patients account for only 5% of all women who have ovarian cancer.<sup>5,22</sup> In high-risk women (with either *BRCA1* or *BRCA2* mutations), oophorectomy is associated with a reduced risk for ovarian and Fallopian tube cancers; however, there is a residual risk for primary peritoneal cancer in these high-risk women after prophylactic salpingo-oophorectomy.<sup>22-25</sup> The risks of surgery include injury to the bowel, bladder, ureter, and vessels.<sup>26</sup> Recently, it has been suggested that the Fallopian tube may be the origin of some ovarian and primary peritoneal cancers.<sup>27-42</sup> Environmental factors have been investigated, but so far they have not been conclusively associated with the development of this neoplasm.

### Screening

Because of the location of the ovaries and the biology of most epithelial cancers, it has been difficult to diagnose ovarian cancer at an earlier, more curable stage. However, evaluations of newly diagnosed ovarian

cancer patients have resulted in consensus guidelines for ovarian cancer symptoms, which may enable earlier identification of patients who may be at an increased risk of having developed early-stage ovarian cancer.<sup>43,44</sup> Symptoms suggestive of ovarian cancer include: bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary symptoms (urgency or frequency), especially if these symptoms are new and frequent (>12 days/month).<sup>43</sup> Physicians evaluating women with this constellation of symptoms must be cognizant of the possibility that ovarian pathology may be causing these symptoms.<sup>45</sup> However, some evidence suggests that the screening test using these symptoms is not as sensitive or specific as necessary, especially in those with early-stage disease.<sup>26,46,47</sup>

An ongoing trial is assessing screening for ovarian cancer (UK Collaborative Trial of Ovarian Cancer Screening [UKCTOCS]) using multimodality screening with ultrasound and cancer antigen 125 (CA-125) versus either ultrasound alone or no screening.<sup>48</sup> Preliminary results suggest that multimodality screening is more effective at detecting early-stage cancer.<sup>49</sup> However, a large randomized trial in more than 78,000 women (the Prostate, Lung, Colorectal, and Ovarian [PLCO] Cancer trial) in the United States found that screening with transvaginal ultrasonography and CA-125 did not decrease mortality from ovarian cancer.<sup>50-52</sup> In addition, false-positive results led to serious complications in some women (n = 163) in the PLCO trial. Another study—comparing 1) CA-125 alone; 2) ultrasound with CA-125; or 3) ultrasound alone—found that CA-125 did not increase the detection of cancer over ultrasound alone and that ultrasound was superior to CA-125 alone.<sup>53</sup>

Randomized data do not yet support routine screening for ovarian cancer in the general population, and routine screening is not currently recommended by any professional society.<sup>26,45,50,54-59</sup> Some physicians

follow women with high-risk factors (eg, those with *BRCA* mutations, those with a family history) using CA-125 monitoring and endovaginal ultrasound;<sup>57</sup> however, prospective validation of these tests remains elusive. An intriguing study suggests that ovarian cancer is associated with unique odors that can be detected.<sup>60,61</sup>

A recent screening trial assessed an algorithm that used age and longitudinal changes in CA-125 levels to determine whether women at average risk would develop ovarian cancer (Risk of Ovarian Cancer Algorithm [ROCA]); women deemed at risk were referred for transvaginal sonography.<sup>62,63</sup> However, until data from larger randomized controlled trials are published (eg, UKCTOCS), there is not enough evidence to support this screening approach for low-risk women.<sup>55,56</sup> Some feel that the ROCA may be useful for high-risk women (eg, those with *BRCA* mutations). The Society of Gynecologic Oncology (SGO) and the FDA have stated that the OVA1 test should not be used as a screening tool to detect ovarian cancer (<https://www.sgo.org/newsroom/position-statements-2/ova1/>). The OVA1 test uses 5 markers (including transthyretin, apolipoprotein A1, transferrin, beta-2 microglobulin, and CA-125) to assess who should undergo surgery by an experienced gynecologic oncologist and who can have surgery in the community. Based on data documenting an increased survival, NCCN Panel Members recommend that all patients should undergo surgery by an experienced gynecologic oncologist (category 1).<sup>45,64-66</sup>

NCCN Panel Members believe that the OvaSure screening test should not be used to detect ovarian cancer.<sup>67-70</sup> The OvaSure test uses 6 biomarkers, including leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125.<sup>71</sup> Although human epididymis protein 4 (HE4) and CA-125 appear to be useful in detecting ovarian cancer,<sup>72,73</sup> recent data show that several markers (including

CA-125, HE4, mesothelin, B7-H4, decoy receptor 3 [DcR3], and spondin-2) do not increase early enough to be useful in detecting early-stage ovarian cancer.<sup>74-76</sup>

### Staging

The NCCN Guidelines for Ovarian Cancer reflect the importance of stage and grade of disease on prognosis and treatment recommendations. Ovarian cancer is classified primarily as stages I to IV. Since 1997, no significant changes have been made in the TNM and FIGO (International Federation of Gynecology and Obstetrics) staging systems for ovarian cancer (see Table 1).<sup>77</sup> Pathologic grading continues to be an important prognostic factor and is used in the selection of therapy, primarily for early-stage disease. Grading is labeled as 1, 2, or 3. Except for those women with stage I, grade 1 tumors (in whom survival is greater than 95% after comprehensive laparotomy), patients in all other stages of ovarian cancer should be encouraged to enter clinical trials for both primary and recurrence therapy. Primary peritoneal adenocarcinoma is staged using the ovarian cancer staging system (see Table 1).<sup>77</sup> Fallopian tube carcinomas are also staged using the TNM and FIGO staging systems (see Table 2).<sup>77</sup>

### Caveat

By definition, the NCCN Practice Guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments. Exceptions to the rule were discussed among panel members during the process of developing these guidelines. A 5% rule (omitting clinical scenarios that comprise less than 5% of all cases) was used to eliminate uncommon clinical occurrences or conditions from these guidelines.

## Epithelial Ovarian Cancer

### Recommended Workup

The NCCN Guidelines for Epithelial Ovarian Cancer begin with the management of an undiagnosed pelvic mass or a prior diagnosis of a malignant epithelial ovarian tumor. Many patients with this diagnosis come to NCCN Member Institutions after having had previous surgery.

### Undiagnosed Pelvic Mass

The primary workup should include an ultrasound and/or abdominal/pelvic CT scan (after an abdominal/pelvic examination) and appropriate laboratory studies for a patient with a suspicious pelvic mass (detected on abdominal/pelvic exam) and/or ascites, abdominal distention, and/or symptoms (ie, bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, urinary symptoms) without other obvious sources of malignancy (see *Workup* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>43,78-84</sup> Tumor markers (including CA-125, inhibin, alpha-fetoprotein [AFP], and beta-human chorionic gonadotropin [beta-HCG]) can be measured if clinically indicated.<sup>85-87</sup> Ultrasound is typically used for initial evaluation; however, CT is useful to assess for metastases.<sup>79</sup> PET/CT scan may be useful for indeterminate lesions.<sup>88-90</sup>

If possible, fine-needle aspiration (FNA) should be avoided for diagnosis of ovarian cancer in patients with presumed early-stage disease to prevent rupturing the cyst and spilling malignant cells into the peritoneal cavity; however, FNA may be necessary in patients with bulky disease who are not surgical candidates.<sup>91-93</sup> Other cancers that should be ruled out include bowel, uterine, and pancreatic cancers or lymphoma;<sup>94,95</sup> benign ovarian and non-ovarian conditions also need to be ruled out (eg, serous cystadenoma).<sup>96</sup>

It has been suggested that specific biomarkers (serum HE4 and CA-125) along with an algorithm (Risk of Ovarian Malignancy Algorithm [ROMA]) may be useful for determining whether a pelvic mass is malignant or benign.<sup>97</sup> The FDA has approved the use of HE4 and CA-125 for estimating the risk for ovarian cancer in women with a pelvic mass. Currently, the NCCN Panel does not recommend the use of these biomarkers for determining the status of an undiagnosed pelvic mass.<sup>98-100</sup> Both primary peritoneal and Fallopian tube cancers are usually diagnosed postoperatively (if there is no major involvement of the ovary) or preoperatively (if there is a biopsy and the patient has already had a bilateral oophorectomy). Primary peritoneal and Fallopian tube cancers are treated in the same manner as epithelial ovarian cancer. Although there is no direct evidence that chest imaging is necessary, panel members felt that it should be part of the overall evaluation of a patient before surgical staging. Additional diagnostic studies, such as gastrointestinal tract evaluation, are not routinely recommended, although they could prove useful in specific clinical situations.

### **Prior Diagnosis of Malignancy**

Patients are often referred to NCCN Member Institutions after having a previous diagnosis of ovarian cancer by surgery or tissue biopsy (cytopathology). Often they have undergone cytoreductive surgery and have undergone comprehensive staging procedures (ie, having met the standards for surgical staging of the Gynecologic Oncology Group [GOG]). However, in some instances, referral occurs after *incomplete* surgery and/or staging (eg, uterus and/or adnexa intact, omentum not removed, residual disease that is potentially resectable, surgical stage not completely documented). The components of surgical staging are listed in the algorithm (see *Principles of Primary Surgery* in the NCCN Guidelines for Epithelial Ovarian Cancer). Identical workup procedures

are recommended for patients having undiagnosed or diagnosed pelvic masses at the time of referral.

Epithelial ovarian cancer has 4 main histologic subtypes (eg, serous, endometrioid, mucinous, clear cell); however, most patients (about 70%) have serous histology.<sup>2,77,101-103</sup> Primary treatment for these histologic subtypes does not differ; they are all treated using the recommendations for epithelial ovarian cancer (see the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>101</sup> However, stage I clear cell carcinoma is treated using recommendations for stage I, grade 3 epithelial ovarian cancer. Pathology review at NCCN Member Institutions is recommended for all patients. The College of American Pathologists (CAP) *Protocol for the Examination of Specimens from Patients With Carcinoma of the Ovary* is a useful tool for pathology reports ([http://www.cap.org/apps/docs/committees/cancer/cancer\\_protocols/2012/Ovary\\_12protocol.pdf](http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/Ovary_12protocol.pdf)).

### **Primary Treatment**

Primary treatment for presumed ovarian cancer consists of appropriate surgical staging and cytoreduction, followed in most (but not all) patients by systemic chemotherapy. Initial surgery should be a comprehensive staging laparotomy, including a total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO).<sup>104</sup> Based on published improved outcomes, it is recommended (category 1) that a gynecologic oncologist perform the primary surgery.<sup>64-66</sup> For a young patient who wishes to maintain fertility, a unilateral salpingo-oophorectomy (USO) (preserving the uterus and contralateral ovary) may be adequate for select stage I tumors (stage 1A and 1C, but not stage 1B) and/or low-risk tumors (ie, early-stage, low-grade invasive tumors; LMP lesions).<sup>105-110</sup>

Comprehensive surgical staging should still be performed to rule out occult higher-stage disease, because data show that approximately 30% of patients undergoing complete staging surgery are upstaged.<sup>111</sup> In early-stage disease, minimally invasive techniques to achieve the surgical goals may be considered in selected patients if performed by an experienced gynecologic oncologist.<sup>84</sup> Minimally invasive techniques may be considered for prophylactic salpingo-oophorectomy.

Cytoreductive surgery is the initial treatment recommendation for patients with clinical stage II, III, or IV disease (see *Primary Treatment* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>66,107,111-114</sup> Although cytoreductive surgery is the standard of care, this recommendation is based on retrospective data (and thus is not a category 1 recommendation).<sup>115</sup> In general, the following procedures (outlined in the next paragraph) should be part of the surgical management of patients with ovarian, Fallopian tube, or primary peritoneal cancer in an effort to fully stage and to achieve maximal cytoreduction to less than 1-cm residual disease or resection of all visible disease in appropriate circumstances.<sup>116-118</sup> Surgical cytoreduction is optimal if the residual tumor nodules are less than 1 cm in maximum diameter or thickness;<sup>104,107,115,119</sup> extensive resection of upper abdominal ovarian metastases is recommended for patients who can tolerate this surgery.<sup>113</sup>

A maximal effort should be made to remove all gross disease. On entering the abdomen, aspiration of ascites or peritoneal lavage should be performed for cytologic examinations. For obvious disease beyond the ovaries, cytologic assessment of ascites and/or lavage specimens will not alter stage or management. Hysterectomy and bilateral salpingo-oophorectomy should be performed. Although total hysterectomy is recommended for most patients, a supracervical hysterectomy is appropriate in some circumstances. An encapsulated

mass should be removed intact, if possible. All involved omentum should be removed. Suspicious and/or enlarged nodes should be resected, if possible.<sup>120,121</sup> Those patients with tumor nodules, outside the pelvis, of 2 cm or less (presumed stage IIIB) should have bilateral pelvic and para-aortic lymph node dissection (see *Principles of Primary Surgery* in the NCCN Guidelines for Epithelial Ovarian Cancer). For young patients who will abruptly enter menopause after surgery, various supportive care measures are available to decrease hot flashes and other symptoms.<sup>122-124</sup>

In patients with advanced ovarian cancer who have had complete debulking, data indicate that overall survival is increased in those who receive systematic lymphadenectomy.<sup>125</sup> Patients with low-volume residual disease after surgical cytoreduction for invasive epithelial ovarian or peritoneal cancer are potential candidates for intraperitoneal (IP) therapy. In these patients, consideration should be given to placement of an IP catheter with initial surgery. Procedures that may be considered for optimal surgical cytoreduction (in all stages) include: radical pelvic dissection, bowel resection, diaphragm or other peritoneal surface stripping, splenectomy, partial hepatectomy, cholecystectomy, partial gastrectomy or cystectomy, ureteroneocystostomy, distal pancreatectomy, or appendectomy.<sup>126</sup>

The therapeutic benefit of neoadjuvant chemotherapy followed by interval cytoreduction remains controversial (see next paragraph).<sup>115,127-132</sup> It may be considered (category 1) for patients with bulky stage III to IV disease who are not surgical candidates; however, a gynecologic oncologist should make this assessment before neoadjuvant chemotherapy is administered.<sup>133-138</sup> Before initiation of chemotherapy, the pathologic diagnosis should be confirmed (by FNA, biopsy, or paracentesis) in this group of patients.

A randomized phase III trial assessed neoadjuvant chemotherapy with interval debulking surgery versus upfront primary debulking surgery in patients with extensive-stage IIIC/IV ovarian, primary peritoneal, and Fallopian tube carcinoma (sponsored by the EORTC-GCG and the NCIC-CTG).<sup>133</sup> Median overall survival was equivalent in these patients (29 vs. 30 months), but patients receiving neoadjuvant chemotherapy with interval debulking surgery had fewer complications.

A major criticism of this International trial is that reported progression-free survival (PFS) and overall survival were inferior to those reported more recently in randomized studies in the United States of patients undergoing primary debulking surgery followed by postoperative intravenous chemotherapy for advanced ovarian cancer (overall survival averages about 50 months).<sup>138,139</sup> Although the median overall survival in the International trial is 20 months lower than that reported in U.S. trials using the customary sequence of therapeutic interventions (ie, primary debulking surgery followed by chemotherapy), this difference may have been a result of selection of higher-risk patients to the International trial (which did not include patients with stage IIIB or earlier-stage cancer). Also, primary or interval debulking surgery in the International trial may not have been optimal (ie, patients may have had >1 cm of residual disease).<sup>115</sup>

In the opinion of the subcommittee for the NCCN Guidelines for Ovarian Cancer, more data will be necessary prior to recommending neoadjuvant chemotherapy in potentially resectable ovarian cancer patients, and upfront debulking surgery remains the treatment of choice in the United States.<sup>140</sup> Note that the authors of the International trial believe that upfront debulking surgery should remain the standard of care for stage IIIB or earlier-stage patients but that neoadjuvant chemotherapy with interval debulking surgery is an option for patients with extensive-stage IIIC/IV disease.<sup>133</sup>

### ***Incompletely Staged Patients***

For patients with incomplete previous surgery and/or staging, treatment recommendations are outlined in the algorithm (see *Diagnosis by Previous Surgery* in the NCCN Guidelines for Epithelial Ovarian Cancer). For patients with stage II to IV disease who have residual disease that is considered unresectable, consider completion surgery after 3 to 6 cycles of chemotherapy. Depending on the surgical results, patients would then receive postoperative chemotherapy. Tumor reductive surgery is recommended for all patients with stage II to IV disease with suspected potentially resectable residual disease.

### ***Chemotherapy***

Most patients with epithelial ovarian cancer receive postoperative systemic chemotherapy. Observation, however, is recommended for patients with stage IA or IB, grade 1 tumors, because survival is greater than 90% for this group with surgical treatment alone.<sup>141-143</sup> If observation (without the addition of chemotherapy) is considered for stage IA or IB, grade 2 tumors, a surgical staging procedure is recommended for all patients. Recommendations regarding initial primary chemotherapy/primary adjuvant therapy include intravenous with [or without] IP options (see *Primary Chemotherapy/Adjuvant Chemotherapy Regimens for Stage II–IV* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>144</sup> All of the regimens (including the combined intravenous/IP chemotherapy) may be used for epithelial ovarian, primary peritoneal, and Fallopian tube cancers. *Principles of Chemotherapy* are also described in the algorithm (see the NCCN Guidelines for Ovarian Cancer). The intravenous/IP chemotherapy regimen (IP chemotherapy) is recommended for stage III patients with optimally debulked (<1 cm residual) disease based on randomized controlled trials (category 1) (<http://www.cancer.gov/clinicaltrials/conducting/developments/ipchemo-digest/Page1>).<sup>139,145,146</sup> Stage II patients may also receive IP

chemotherapy, although no randomized evidence for stage II has been published. In women with stage III cancer, survival was increased by 16 months after IP therapy using cisplatin/paclitaxel when compared with standard intravenous therapy (65.6 vs. 49.7 months,  $P = .03$ ) in the GOG 172 trial. For patients for whom this does not apply (eg, those with poor performance status [PS]), the combination of intravenous paclitaxel plus carboplatin (category 1) may be used (see *Primary Chemotherapy/Primary Adjuvant Therapy* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>64,147</sup> Intravenous docetaxel plus carboplatin (category 1)<sup>148</sup> or paclitaxel plus cisplatin (category 1) are options for alternative regimens.<sup>149</sup> The docetaxel/carboplatin regimen may be considered for patients who are at high risk for neuropathy (eg, patients with diabetes). Recommendations for the number of cycles of treatment vary with the stage of the disease. For patients with advanced-stage disease (stages II–IV), 6 to 8 cycles of chemotherapy are recommended, whereas 3 to 6 cycles are recommended for earlier-stage disease.<sup>150</sup> Some clinicians feel there is a potential survival advantage for 6 cycles of chemotherapy in patients with serous cytology.<sup>151</sup>

The recommended intravenous regimens accepted by a consensus of the NCCN Panel include: 1) paclitaxel, 175 mg/m<sup>2</sup> over 3-hour intravenous infusion, followed by carboplatin, dosed at an area under the curve (AUC) of 5 to 7.5 intravenous over 1 hour on day 1, given every 3 weeks for 6 cycles (category 1);<sup>147,152</sup> 2) docetaxel, 60 to 75 mg/m<sup>2</sup> 1-hour intravenous infusion followed by carboplatin, dosed at AUC of 5 to 6 intravenous over 1 hour on day 1, every 3 weeks for 6 cycles (category 1);<sup>148</sup> and 3) dose-dense paclitaxel, 80 mg/m<sup>2</sup> intravenous over 1 hour on days 1, 8, and 15 plus carboplatin AUC 6 intravenous over 1 hour on day 1, every 3 weeks for 6 cycles (category 1).<sup>153</sup> Note that carboplatin dosing may be revised based on changes in

serum creatinine methodology (<http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm228974.htm>).

The recommended IP chemotherapy regimen is paclitaxel, 135 mg/m<sup>2</sup> continuous intravenous infusion over 3 or 24 hours on day 1; cisplatin 75 to 100 mg/m<sup>2</sup> IP on day 2 after intravenous paclitaxel; paclitaxel, 60 mg/m<sup>2</sup> IP on day 8; repeat every 3 weeks times 6 cycles (category 1).<sup>139</sup> The published randomized trial for this IP/intravenous regimen used intravenous continuous infusion of paclitaxel over 24 hours. A 3-hour infusion of paclitaxel has not been proven to be equivalent to a 24-hour infusion, although a 3-hour infusion has been reported to be more convenient, easier to tolerate, and less toxic.<sup>154</sup> Note that these IP regimens include intravenous regimens so that systemic disease can also be treated.

These regimens have different toxicity profiles. The docetaxel/carboplatin regimen is associated with increased risk for neutropenia; the intravenous paclitaxel/carboplatin regimen is associated with sensory peripheral neuropathy, and dose-dense paclitaxel is associated with increased anemia.<sup>148,152,153</sup> The IP paclitaxel/cisplatin regimen is associated with leukopenia, infection, fatigue, renal toxicity, abdominal discomfort, and neurotoxicity.<sup>155,156</sup> In the initial studies, only 42% of women were able to complete all 6 treatment cycles (of the IP regimen) because of toxicity; however, with more experience, this percentage has improved in the major cancer centers.<sup>157</sup> Using a lower IP cisplatin dose of 75 mg/m<sup>2</sup> or splitting the dose may help to decrease toxicity.<sup>154,157,158</sup> This approach is currently under investigation in an ongoing GOG clinical trial.

Patients considered for the IP cisplatin and IP/intravenous paclitaxel regimen should have normal renal function before starting, a medically



appropriate PS based on the future toxicities of the IP/intravenous regimen, and no previous evidence of medical problems that could significantly worsen during chemotherapy (eg, preexisting neuropathy) (see *Principles of Chemotherapy* in the NCCN Guidelines for Epithelial Ovarian Cancer). Reasons for discontinuing the IP regimen included catheter complications, nausea/vomiting/dehydration, and abdominal pain.<sup>159</sup> Women unable to complete IP therapy should receive intravenous therapy. Techniques to decrease catheter complications include catheter choice and timing of insertion.<sup>145,160</sup> Expert nursing care may help to decrease complications.<sup>144</sup> Giving intravenous hydration before and after IP chemotherapy is a useful strategy to prevent renal toxicity.<sup>157</sup> After chemotherapy, patients often require intravenous fluids (5–7 days) in the outpatient setting to prevent or help treat dehydration. Whether to use IP or intravenous chemotherapy remains controversial.<sup>159,161-164</sup>

Patients with poor PS, comorbidities, stage IV disease, or advanced age may not tolerate the IP regimen. The IP regimen published by Armstrong et al has, however, documented the longest median survival (65.6 months) that has been described to date in optimally debulked stage III patients.<sup>139,165</sup> A recent study reported overall survival of 110 months in patients with stage III ovarian cancer and no residual disease who received the IP regimen.<sup>165</sup> Patients with primary peritoneal cancer, Fallopian tube cancer, or MMT can also be considered for IP chemotherapy.<sup>146,160</sup> All women should be counseled about the clinical benefit associated with combined intravenous and IP chemotherapy administration before undergoing surgery for epithelial ovarian cancer, Fallopian tube cancer, primary peritoneal cancer, or MMT. A recent study reported that women with aberrant *BRCA1* expression had increased survival when treated with IP cisplatin/paclitaxel.<sup>166</sup>

Dose-dense weekly paclitaxel with carboplatin has been shown to increase both PFS (28 vs. 17 months,  $P = .0015$ ) and 3-year overall survival (72% vs. 65%,  $P = .03$ ) when compared with standard therapy given every 3 weeks (ie, intravenous carboplatin/paclitaxel) in women with advanced epithelial ovarian cancer.<sup>153</sup> After 5 years, overall survival was 58.6% versus 51% ( $P = .044$ ).<sup>167</sup> However, the dose-dense regimen is more toxic, and patients discontinued dose-dense paclitaxel therapy more often than did those receiving standard therapy. Future studies will compare the effect of weekly paclitaxel on the overall survival benefit with that of using IP chemotherapy.<sup>168</sup> A recent phase II study reported that dose-dense paclitaxel/carboplatin regimen yielded overall survival of 31.5 months, which is inferior to the median survival with an IP regimen (61 months).<sup>165,169</sup>

### **Anti-Angiogenesis Agents**

A recent phase III randomized trial (GOG 0218) assessed bevacizumab combined with carboplatin/paclitaxel in the upfront setting compared to carboplatin/paclitaxel alone. The median PFS was significantly increased (14.1 vs. 10.3 months,  $P < .001$ ) in patients receiving prolonged bevacizumab (upfront and as maintenance therapy) when compared with chemotherapy alone.<sup>170,171</sup> However, PFS was not significantly increased in patients who did not receive maintenance bevacizumab (upfront with placebo maintenance) versus chemotherapy alone (ie, bevacizumab/carboplatin/paclitaxel vs. carboplatin/paclitaxel). Quality of life was not improved in GOG 0218.<sup>172</sup>

Another phase III randomized trial (ICON7) also assessed bevacizumab/carboplatin/paclitaxel in the upfront setting. The trial design of ICON7 differs from GOG 0218 (see next paragraph).<sup>173,174</sup> Although the PFS data from ICON7 confirm the findings of GOG 0218, the benefits appear to be modest (2.4-month increase in PFS) and mature survival data have not been reported.<sup>172,173</sup>

Panel members had a major disagreement about recommending the addition of bevacizumab to up-front chemotherapy with carboplatin/paclitaxel or using bevacizumab as maintenance therapy, which is reflected in the category 3 recommendations for these regimens (see *Primary Chemotherapy/Adjuvant Chemotherapy Regimens for Stage II–IV* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>175</sup> Many panel members believe that bevacizumab should not be added to up-front chemotherapy in patients with ovarian cancer, because data from these 2 phase III randomized trials (ie, GOG-0218, ICON7) have not shown a statistically significant increase in overall survival and/or improved quality of life.<sup>171,172,174,176-178</sup>

The NCCN Panel recommends (category 3) that if bevacizumab is used with upfront chemotherapy followed by maintenance therapy, then either the GOG-0218 or ICON7 regimens should be used (see *Primary Chemotherapy/Adjuvant Chemotherapy Regimens for Stage II–IV* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>171,174</sup> The only GOG-0218 regimen that is recommended (category 3) is the prolonged bevacizumab regimen (upfront with carboplatin/paclitaxel followed by maintenance bevacizumab).<sup>171</sup> This topic is discussed in greater detail in a recent JNCCN Guidelines Insight on Ovarian Cancer.<sup>175</sup> The NCCN Panel encourages participation in ongoing clinical trials that are further investigating the role of anti-angiogenesis agents in the treatment of ovarian cancer, both in the upfront and recurrence settings.<sup>179</sup>

### **Number of Chemotherapy Cycles and Agents**

Panel members had an extensive discussion about the number of cycles of chemotherapy that should be recommended for patients with advanced-stage disease. There is no evidence confirming that more than 6 to 8 cycles of combination chemotherapy are required for initial chemotherapy.<sup>180</sup> Patients can also have 3 to 6 cycles of chemotherapy followed by completion surgery and then postoperative chemotherapy

(see *Primary Treatment* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>130</sup>

The role of maintenance (or postremission) therapy in patients who achieve a complete clinical remission after 6 to 8 cycles of chemotherapy is an option based on the results from GOG 178. This trial randomly assigned patients to 3 versus 12 months of further paclitaxel (135–175 mg/m<sup>2</sup> every 4 weeks for 12 cycles) after initial chemotherapy.<sup>181</sup> The published study treated patients at 175 mg/m<sup>2</sup>; the plan was to decrease the dose to 135 mg/m<sup>2</sup>, but the protocol closed before any patients were treated at the lower dose. The results of this trial suggest that patients receiving 12 months of therapy sustained a PFS advantage. However, postremission paclitaxel chemotherapy is a category 2B recommendation because it is associated with toxicity and it only increased PFS. Another study suggests that postremission paclitaxel is not beneficial.<sup>182</sup> Note that a category 2B recommendation is based on lower level evidence (eg, phase II randomized trials) and a majority vote (>50% but <85%) from panel members who agree that the intervention is appropriate.

### **Drug Reactions**

Virtually all drugs have the potential to cause drug reactions, either during or after the infusion.<sup>183-185</sup> Drugs used in gynecologic oncology treatment that more commonly cause adverse reactions include carboplatin, cisplatin, docetaxel, liposomal doxorubicin, oxaliplatin, and paclitaxel. Drug reactions can occur with either intravenous or IP administration of these drugs.<sup>186</sup> Most of these drug reactions are mild infusion reactions (ie, skin reactions, cardiovascular reactions, respiratory or throat tightness), but more severe allergic reactions (ie, life-threatening anaphylaxis) can occur.<sup>187,188</sup> Infusion reactions are more common with paclitaxel,<sup>189</sup> but mild reactions can also occur with liposomal doxorubicin.<sup>190</sup> Allergic reactions (ie, true drug allergies) are

more common with platinum agents (ie, carboplatin, cisplatin, oxaliplatin).<sup>189,191</sup>

Management of drug reactions is discussed in the NCCN Guidelines for Ovarian Cancer. Algorithms are provided for management of mild, severe, and life-threatening reactions.<sup>192</sup> These drug reaction algorithms are also useful for patients with other gynecologic cancers (eg, cervical and uterine cancers) who are receiving carboplatin, cisplatin, docetaxel, liposomal doxorubicin, oxaliplatin, or paclitaxel. Typically, the infusion should be stopped for patients having a reaction; further management is provided in the algorithms. Standard resuscitation procedures (ie, Advanced Cardiac Life Support [ACLS]) should be followed for patients with acute cardiopulmonary arrest (<http://acls-algorithms.com/2010-acls-guidelines>).<sup>193</sup>

For patients with allergic reactions, various desensitization protocols have been published and should be followed. To maximize safety, patients may be desensitized in the intensive care unit.<sup>185</sup> Almost all patients can be desensitized (about 90%).<sup>185</sup> For severe life-threatening reactions, the implicated agent should not be used again unless under the supervision and guidance of an allergist or specialist with expertise in desensitization. If a mild allergic reaction is suspected, and it is appropriate to administer the drug again, a desensitization regimen should be used even if the symptoms have resolved.<sup>183</sup> Patients must be desensitized with each infusion if they previously had a drug reaction.<sup>194-196</sup> Data suggest that an extended infusion schedule and use of premedication may decrease the number of hypersensitivity reactions to carboplatin.<sup>197</sup> Skin testing is associated with false-negative results.<sup>198,199</sup>

### **Radiation Therapy**

Whole abdominal radiation therapy (WART) in patients with low-bulk stage III disease is no longer included as an option for initial treatment or consolidation treatment in ovarian cancer. Because WART is rarely used in NCCN Member Institutions, it is not included as a treatment recommendation in the NCCN Guidelines for Ovarian Cancer. Palliative localized RT is an option for symptom control in patients with recurrent disease (see *Acceptable Recurrence Therapies* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>200-204</sup> Patients who receive radiation are prone to vaginal stenosis, which can impair sexual function. Women can use vaginal dilators to prevent or treat vaginal stenosis. Dilator use can start 2 to 4 weeks after RT is completed and can be done indefinitely ([http://www2.mskcc.org/patient\\_education/assets/downloads-english/571.pdf](http://www2.mskcc.org/patient_education/assets/downloads-english/571.pdf)).

### **Recommendations After Primary Treatment**

After initial treatment (eg, 6 cycles of chemotherapy), patients should undergo a clinical re-evaluation. Patients who have no evidence of progression of cancer (ie, complete clinical remission) after initial treatment can undergo observation with follow-up (see next section on *Follow-Up Recommendations*) (also see *Monitoring/Follow-up* in the NCCN Guidelines for Epithelial Ovarian Cancer); other options are discussed below. Patients with partial remission or progression during initial treatment should be treated with second-line approaches (see section on *Recurrent Disease* in this Discussion) (see *Therapy for Persistent Disease or Recurrence* in the NCCN Guidelines for Epithelial Ovarian Cancer).

Options for maintenance treatment—for the management of advanced-stage (stages II–IV) patients who are in complete clinical remission after their initial therapeutic regimen—include observation

alone, a clinical trial, or additional chemotherapy<sup>181</sup> (paclitaxel, category 2B), preferably in a controlled clinical trial (see *Secondary Adjuvant Therapy* in the NCCN Guidelines for Epithelial Ovarian Cancer). If used, the paclitaxel regimen is 135 to 175 mg/m<sup>2</sup> every 4 weeks for 12 cycles. Note that complete clinical remission is defined as no objective evidence of disease (ie, negative physical examination, negative CA-125 levels, negative CT with <1 cm lymph nodes).

### Follow-up Recommendations

After the completion of primary surgery and chemotherapy in patients with all stages of ovarian cancer (or Fallopian tube cancer or primary peritoneal cancer) who have a complete response, the standard recommendation is observation with follow-up. Recommendations for monitoring are described in the algorithm (see *Monitoring/Follow-up* in the NCCN Guidelines for Epithelial Ovarian Cancer).

Chest/abdominal/pelvic CT, MRI, PET scans (category 2B for PET), PET-CT, and chest imaging may be ordered if clinically necessary.<sup>205-208</sup>

Patients should be educated about the signs and symptoms suggestive of recurrence (eg, pelvic pain, bloating, early satiety, obstruction, weight loss, fatigue). Patients who chose fertility-sparing surgery should be monitored by ultrasound examinations if necessary; completion surgery should be considered (category 2B) after they finish childbearing.

If the CA-125 level was initially elevated, the measurement of a CA-125 level or other tumor markers at each follow-up evaluation is recommended. A multi-institutional European trial assessed the use of CA-125 for monitoring for ovarian cancer recurrence after primary therapy.<sup>209-211</sup> The data suggest that treating recurrences early (based on detectable CA-125 levels in asymptomatic patients) is not associated with an increase in survival and is associated with a decrease in quality of life.<sup>212</sup> Recent recommendations from the SGO state that use of

CA-125 levels for surveillance is optional.<sup>207</sup> The NCCN Panel concurs with the SGO opinion, which states that the European trial has limitations and that patients should discuss the pros and cons of CA-125 monitoring with their physicians (<https://www.sgo.org/newsroom/position-statements-2/use-of-ca125-for-monitoring-ovarian-cancer/>). In addition, patients seem reluctant to give up monitoring.<sup>213</sup> Others have discussed this study in greater detail.<sup>214-216</sup>

### Management of an Increasing CA-125 Level

The management of patients in a clinical complete remission—who (during routine monitoring and follow-up) are found to have an increasing CA-125 level but no signs or symptoms of recurrent disease (eg, pelvic pain, bloating, obstruction), following an evaluation including a negative pelvic examination and negative chest/abdominal/pelvic CT scans—is somewhat controversial. Patients who have never received chemotherapy (ie, naïve to chemotherapy) should be managed as newly diagnosed patients, should undergo clinically appropriate imaging studies and surgical debulking, and should be treated as previously described (see *Primary Treatment* in the NCCN Guidelines for Epithelial Ovarian Cancer).

After the documentation of an increased CA-125 level (ie, biochemical relapse), the median time for a clinical relapse is 2 to 6 months. However, data suggest that immediate treatment for biochemical relapse is not beneficial; therefore, immediate treatment is a category 2B recommendation in the NCCN Guidelines.<sup>209</sup> After biochemical relapse, recommended options include enrollment on a clinical trial or delaying treatment (ie, observation) until clinical symptoms arise (see *Recurrent Disease* in the NCCN Guidelines for Epithelial Ovarian Cancer). Because tamoxifen and other hormonally active agents have a defined response rate for patients with recurrent disease who have progressed after platinum-based chemotherapy,<sup>217</sup> these agents are



frequently administered to patients who have only a rising CA-125 level<sup>218</sup> as evidence of tumor progression.<sup>219</sup> Tamoxifen, other hormonal agents, or other recurrence therapy are acceptable recommendations for this clinical situation (category 2B).

### Recurrent Disease

The prognosis is poor either 1) for patients who progress after 2 consecutive chemotherapy regimens without ever sustaining a clinical benefit (refractory),<sup>220</sup> or 2) for those whose disease recurs in less than 6 months (platinum resistant). Note that progression is typically defined using traditional RECIST (Response Evaluation Criteria in Solid Tumor) criteria (ie, a 20% increase in tumor diameter).<sup>221</sup> Panel members emphasized the importance of clinical trials to identify agents active in this group of patients. Because these patients were resistant to their primary induction regimen, retreatment with a platinum compound or paclitaxel is not generally recommended. Although panel members do not recommend retreatment with platinum agents, they recognize that altering the schedule of paclitaxel may produce secondary responses.<sup>222,223</sup> Before any drug is given in the recurrent setting, the clinician should be familiar with the drug's metabolism and should make certain that the patient is an appropriate candidate for the drug (eg, that the patient has adequate renal or hepatic function). Clinical judgment must be used when selecting postoperative chemotherapy.

Options for platinum-resistant patients or for those with stages II to IV disease who have a partial response include recurrence therapy (see *Acceptable Recurrence Therapies* in the NCCN Guidelines for Epithelial Ovarian Cancer),<sup>224</sup> clinical trial, or observation (category 2B for observation). Patients who relapse 6 months or more after initial chemotherapy are termed *platinum sensitive*.<sup>225,226</sup> Combination platinum-based chemotherapy is preferred for first recurrence (category

1) in platinum-sensitive patients (see *Therapy for Persistent Disease or Recurrence* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>226</sup> Possible regimens are discussed in the following section (see *Acceptable Recurrence Modalities*).

Patients with ovarian cancer will often be retreated with multiple courses of recurrence therapy. Caution should be used in patients who receive multiple sequential courses of chemotherapy, because they may experience excessive toxicity and may not be able to tolerate doses used for first-line recurrence therapy; thus, clinical judgment should be used when selecting doses (see *Principles of Chemotherapy* in the NCCN Guidelines for Epithelial Ovarian Cancer). Potential ancillary palliative surgical and/or supportive care procedures for selected patients are summarized in the algorithm (see *Principles of Primary Surgery* in the NCCN Guidelines for Epithelial Ovarian Cancer) (<http://emedicine.medscape.com/article/270646-overview#aw2aab6b4>).<sup>227-232</sup> The SGO has a position statement on *Principles of Palliative Care* (<https://www.sgo.org/newsroom/position-statements-2/delivery-of-palliative-care-services/>).

Secondary cytoreductive surgery can be considered for patients who recur (ie, radiographic and/or clinical relapse) after a long disease-free interval (6 months or more).<sup>115,233,234</sup> A recent meta-analysis suggests that survival increases for patients with recurrent disease who have complete cytoreduction.<sup>116</sup> The duration of the disease-free interval has not been established, although panel members agreed that it should be at least 6 months before surgery should be considered.<sup>235</sup>

### Acceptable Recurrence Modalities

The NCCN Panel felt that no single therapeutic agent should be currently recommended as the treatment of choice for recurrent ovarian carcinoma. However, some agents are preferred based on expert

opinion (primarily for reasons of decreased toxicity and/or marginally increased effectiveness) (see *Acceptable Recurrence Therapies* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>144</sup> A meta-analysis of 13 randomized studies in recurrent ovarian cancer has been published.<sup>225</sup>

The consensus of the NCCN Panel for the treatment of recurrent disease is shown in the algorithm (see *Acceptable Recurrence Therapies* in the NCCN Guidelines for Epithelial Ovarian Cancer). Platinum-based combination chemotherapy is recommended (category 1) for platinum-sensitive recurrence (see *Therapy for Persistent Disease or Recurrence* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>225,226</sup> Preferred combinations for platinum-sensitive recurrent disease include carboplatin/paclitaxel (category 1),<sup>226</sup> carboplatin/weekly paclitaxel,<sup>153</sup> carboplatin/docetaxel,<sup>236,237</sup> carboplatin/gemcitabine (which has been shown to improve progression-free survival),<sup>226,238,239</sup> carboplatin/liposomal doxorubicin (also has been shown to improve progression-free survival),<sup>240</sup> or cisplatin/gemcitabine.<sup>238</sup>

For platinum-resistant disease, the preferred agent is a single non-platinum-based agent (ie, docetaxel, oral etoposide, gemcitabine, liposomal doxorubicin, weekly paclitaxel, topotecan); sequential therapy using single agents is typically used.<sup>241</sup> The response rate of the following agents appears to be similar: topotecan, 20%;<sup>242</sup> gemcitabine, 19%;<sup>243,244</sup> vinorelbine, 20%;<sup>245,246</sup> liposomal doxorubicin, 26%;<sup>243,244,247</sup> and oral etoposide, 27%.<sup>248</sup> In platinum-resistant patients, the response rate for docetaxel is 22% and for weekly paclitaxel is 21%.<sup>222,249,250</sup> For platinum-sensitive disease in patients who cannot tolerate combination therapy, the preferred single agent is carboplatin or cisplatin.<sup>238,239</sup> Recent reports suggest that weekly topotecan is less toxic than the daily regimen.<sup>251,252</sup>

Other potentially active agents include altretamine, capecitabine, cyclophosphamide, ifosfamide, irinotecan, melphalan, oxaliplatin, paclitaxel, nanoparticle albumin-bound paclitaxel (ie, nab-paclitaxel), pemetrexed, and vinorelbine (see *Acceptable Recurrence Therapies* in the NCCN Guidelines for Epithelial Ovarian Cancer). Nab-paclitaxel has an overall response rate of 64%.<sup>253</sup> Altretamine has a 14% response rate<sup>254</sup> and ifosfamide has a 12% response rate,<sup>255</sup> although less information regarding their use in paclitaxel-refractory patients is available. In platinum-resistant patients, the response rate for pemetrexed is 21%.<sup>222,249,250</sup> Bevacizumab is also active (21%) in both platinum-sensitive and platinum-resistant patients,<sup>172,256-260</sup> although it may cause hypertension, arterial thrombosis, or intestinal perforation.

Several trials are assessing combination therapy with bevacizumab for recurrent ovarian cancer (ie, OCEANS, AURELIA).<sup>261-263</sup> A phase III randomized trial (OCEANS) assessed carboplatin/gemcitabine with and without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer who had not previously received bevacizumab. In the OCEANS trial, PFS was increased in patients receiving the chemotherapy/bevacizumab arm when compared with chemotherapy alone (12.4 vs. 8.4 months,  $P < .0001$ ).<sup>262</sup> Combination therapy with bevacizumab is a category 2B recommendation because there is less consensus among the NCCN Panel (>50% but < 85%) that this intervention is appropriate. Panel members feel other combination regimens are more beneficial and effective than those with bevacizumab. In addition, the carboplatin/gemcitabine/bevacizumab regimen is only recommended in patients who have not previously received bevacizumab. Based on 2 phase II trials, panel members feel that bevacizumab alone is useful in patients who have recurrent disease (especially those with ascites), which is reflected in the category 2A recommendation for single-agent bevacizumab.<sup>241,258,259,264</sup>

Taxanes (including docetaxel and paclitaxel) and platinum compounds (including cisplatin, carboplatin, and oxaliplatin) can be used in appropriate patients.<sup>181,226,265</sup> Capecitabine has activity in patients resistant to platinum and taxanes.<sup>266</sup> Other alkylating agents, including cyclophosphamide and melphalan, can also be used. In addition, for patients who cannot tolerate or have not responded to cytotoxic regimens, hormonal therapy with tamoxifen or other agents (including anastrozole, letrozole, leuprolide acetate, or megestrol acetate) continues to be a viable therapeutic option.<sup>267-272</sup>

Recent data suggest that olaparib (AZD2281), which is a PARP (poly ADP-ribose polymerase) inhibitor, is active in select patients (those with *BRCA-1* and *BRCA-2* mutations have higher response rates than *BRCA*-negative patients) with chemotherapy-refractory ovarian cancer, especially those with platinum-sensitive disease.<sup>241,273-277</sup> Patients who are resistant or refractory to platinum have a lower response rate to olaparib.<sup>273,275,276</sup> A phase II study found that olaparib was similar to pegylated liposomal doxorubicin. Note that olaparib is not FDA approved for this indication and is only available in a clinical trial. Localized RT can also provide effective palliation when radiation ports are tailored to specific symptomatic disease sites.<sup>200,201</sup>

Chemotherapy/resistance assays and/or other biomarker assays are being used in some NCCN Member Institutions to aid in selecting chemotherapy in situations where there are multiple equivalent chemotherapy options available; however, the current level of evidence (category 3) is not sufficient to supplant standard-of-care chemotherapy.<sup>278,279</sup> Thus, the NCCN Panel felt that *in vitro* chemosensitivity testing to choose a chemotherapy regimen for recurrent disease situations should not be recommended (category 3), owing to the lack of demonstrable efficacy for such an approach. The

ASCO also does not recommend use of chemotherapy sensitivity and resistance assays, unless in a clinical trial setting.<sup>280</sup>

However, regardless of which regimen is selected initially, reevaluation should follow after 2 to 4 cycles of chemotherapy (depending on the agent) to determine if patients benefited from chemotherapy. Patients who primarily progress on 2 consecutive chemotherapy regimens without evidence of clinical benefit may not benefit from additional therapy.<sup>220</sup> Decisions to offer supportive care, additional therapy, or clinical trials should be made on a highly individual basis.

### Borderline Epithelial Ovarian Cancer (Low Malignant Potential)

#### Diagnosis

Borderline epithelial ovarian cancer (also known as ovarian cancer of LMP, borderline ovarian cancer) is a primary epithelial ovarian lesion with cytologic characteristics suggesting malignancy but without frank invasion and with a clinically indolent course and good prognosis.<sup>281</sup> Five-year survival exceeds 80%.<sup>282</sup> In contrast to patients with frankly invasive ovarian carcinoma, women with borderline disease tend to be younger and are often diagnosed with stage I disease.<sup>283,284</sup>

The characteristic pathologic hallmark of typical epithelial ovarian cancer is the identification of peritoneal implants, which microscopically and/or macroscopically invade the peritoneum. Borderline epithelial ovarian cancer has the visual appearance of peritoneal carcinomatosis. However, microscopic evaluation fails to reveal evidence of frank invasion by the tumor nodules, although rarely invasive implants (which continue to be consistent with the diagnosis of LMP lesions) can be identified microscopically by the pathologist.



Some investigators feel that the appearance of invasive implants on the peritoneal surfaces in patients having ovarian cancer of LMP portends a less favorable prognosis; therefore, the same treatments used for epithelial ovarian cancer (ie, postoperative chemotherapy) can be considered (category 2B) for these patients (see *Primary Treatment* in the NCCN Guidelines for Borderline Epithelial Ovarian Cancer).<sup>283-285</sup>

The benefit of postoperative chemotherapy has not been demonstrated for patients who have no microscopically demonstrable invasive implants; therefore, observation is recommended for these patients.<sup>286</sup>

### Treatment

Treatment guidelines for borderline epithelial ovarian cancer depend on the histologic and clinical characteristics, the age of the patient,<sup>284</sup> and the stage of the disease at the time of diagnosis. Patients should be evaluated by a gynecologic oncologist. At NCCN Member Institutions, patients may be initially evaluated with an undiagnosed pelvic mass or with an established diagnosis of ovarian cancer of LMP. For the 2013 update, panel members are now less likely to recommend aggressive surgery; observation is one of several possible approaches. Patients with an LMP lesion who desire to maintain their fertility may undergo surgery limited to a USO (preserving the uterus, contralateral ovary, and contralateral Fallopian tube) at the time of comprehensive staging.<sup>106,107,287</sup> If the patient does not desire fertility-sparing surgery, observation or standard ovarian cancer debulking surgery is recommended. However, data do not show increased survival with lymphadenectomy and omentectomy for LMP, although upstaging does occur.<sup>288,289</sup>

For patients with known LMP disease who had incomplete previous surgery and/or were incompletely staged at the time of their initial laparotomy, recommendations depend on whether invasive implants are

present and whether fertility preservation is desired (see *Primary Treatment for Incomplete Previous Surgery* in the NCCN Guidelines for Borderline Epithelial Ovarian Cancer). Patients who want to preserve their fertility should have comprehensive fertility-sparing surgical staging (if not previously done).

### Follow-up

Treatment recommendations after comprehensive staging depend on the presence or absence of invasive implants. The initial therapeutic approach for patients having invasive implants may include observation or, alternatively, consideration can be given to treating patients according to the guidelines for epithelial ovarian cancer (category 2B for postoperative chemotherapy) (see *Primary Treatment* in the NCCN Guidelines for Borderline Epithelial Ovarian Cancer).<sup>290</sup> Patients with no invasive implants should be observed and monitored (see *Monitoring/Follow-Up* in the NCCN Guidelines for Borderline Epithelial Ovarian Cancer).<sup>283,291</sup>

Patients who chose fertility-sparing surgery should be monitored by ultrasound examinations if necessary. After child-bearing is completed, completion surgery should be considered (category 2B). At the time of clinical relapse, a surgical evaluation and debulking are recommended if appropriate. Patients who have invasive disease at this time may be treated using the Guidelines for Epithelial Ovarian Cancer (category 2B) (see *Primary Chemotherapy/Primary Adjuvant Therapy* in the NCCN Guidelines for Borderline Epithelial Ovarian Cancer); those without invasive implants should be observed.



### Less Common Ovarian Histopathologies

#### Overview

Less common histopathologies of ovarian cancer include: malignant germ cell neoplasms, carcinosarcoma (MMMT), and malignant sex cord-stromal tumors. These tumors account for approximately 5% of all ovarian cancers and differ from epithelial ovarian cancer in their biology and recommended approaches to treatment. In contrast to epithelial ovarian cancer, many patients with these tumors present at an early stage and tumors may be confined to one ovary; thus, some of these patients are candidates for fertility-sparing surgery. The diagnosis of less common ovarian histopathologies (LCOH) is often not made until after surgery.

#### Recommended Workup

The NCCN Guidelines recognize that patients may obtain consultation at an NCCN Member Institution for recommendations and treatment of an undiagnosed pelvic mass, or for management of a previously biopsied malignant ovarian tumor. Many such patients come to NCCN Member Institutions after having had previous surgery at other institutions. Patients having a histologically undiagnosed pelvic mass should undergo evaluation and staging as described in the algorithm (see *Workup* in the NCCN Guidelines for Less Common Ovarian Histopathologies). Tumor markers (including CA-125, inhibin, AFP, and beta-HCG) can be measured if clinically indicated.

Patients desiring to potentially maintain fertility should have an intraoperative frozen section evaluation. Fertility-sparing surgery may be performed (if technically feasible) if the frozen section results are positive for malignant germ cell tumor, ovarian cancer of LMP, or clinical stage I epithelial ovarian or stromal tumors.<sup>106,107,110,292-295</sup> Patients who do not desire fertility preservation; those who have a clinical stage II, III,

or IV epithelial ovarian cancer or stromal tumor; or those with carcinosarcoma (MMMT) should undergo comprehensive surgical staging as per the ovarian cancer guidelines (see *Principles of Primary Surgery* in the NCCN Guidelines for Ovarian Cancer).

Patients may have been referred to an NCCN Member Institution after receiving histologic confirmation of an ovarian neoplasm of a less common type. The recommended initial surgical recommendation depends on the specific histologic diagnosis. Often, patients have been comprehensively staged (having met the standards for surgical staging of the GOG) and have undergone cytoreductive surgery. However, in some instances, they are referred after having had *incomplete* staging (ie, uterus and/or adnexa intact, omentum not removed, surgical stage not documented).

#### Malignant Germ Cell Tumors

These tumors include dysgerminomas, immature teratomas, embryonal tumors, and endodermal sinus (yolk sac) tumors; they mainly occur in younger women who are often diagnosed with stage I disease.<sup>296,297</sup> The recommended workup (see *Recommended Workup* as previously discussed) for malignant germ cell tumors may include pulmonary function studies if bleomycin is being considered.<sup>85,298</sup> Women younger than 35 years with a pelvic mass should have AFP levels measured to assess for germ cell tumors.<sup>85-87</sup> Malignant germ cell tumors have an excellent prognosis. After appropriate treatment, 5-year survival is more than 85%.<sup>296,299,300</sup>

Completion surgery with comprehensive staging is recommended as initial surgery for patients who do not desire fertility preservation. The staging system for ovarian and primary peritoneal cancer is also used for malignant germ cell tumors (see Table 1). After comprehensive surgical staging, observation is recommended for patients with stage I

dysgerminoma or immature teratoma.<sup>301</sup> If these patients have had incomplete surgical staging, recommended options depend on the type of tumor, the results of imaging and tumor marker testing (eg, AFP and beta-HCG), and whether the patient desires fertility preservation (see *Malignant Germ Cell Tumors* in the NCCN Guidelines for Less Common Ovarian Histopathologies).

Fertility-sparing surgery should be considered for those desiring fertility preservation, regardless of stage (see *Primary Treatment for Malignant Germ Cell Tumors* in the NCCN Guidelines for Less Common Ovarian Histopathologies).<sup>110,297,300,302,303</sup> Patients who chose fertility-sparing surgery should be monitored by ultrasound examinations if necessary; completion surgery (category 2B) should be considered after finishing childbearing.

After surgery, surveillance is the recommended option for patients with stage I dysgerminoma or stage I, grade I immature teratoma based on European and pediatric reports.<sup>297</sup> For patients with stage II to IV malignant germ cell tumors, postoperative chemotherapy is recommended. Patients should receive postoperative chemotherapy for 3 to 4 cycles with bleomycin/etoposide/platinum (BEP) (category 2B for 3 vs. 4 cycles) if they have: 1) embryonal or endodermal sinus tumors; 2) stages III to V dysgerminoma; or 3) stage I, grade 2 to 3, or stage II to IV immature teratoma.<sup>298,304-306</sup> If considering the use of bleomycin, pulmonary function tests are recommended.<sup>298,299</sup> In select patients with stage IB to III dysgerminoma for whom minimizing toxicity is critical, 3 courses of etoposide/carboplatin can be used (carboplatin 400 mg/m<sup>2</sup> [AUC =~5–6] on day 1 plus etoposide 120 mg/m<sup>2</sup> on days 1–3 every 4 weeks for 3 courses).<sup>307</sup> Dose reductions or delays are not recommended even in the setting of neutropenia.

Patients achieving a complete clinical response after chemotherapy should be observed clinically every 2 to 4 months with AFP and beta-HCG levels (if initially elevated) for 2 years. For those with abnormal markers and definitive recurrent disease, options (category 2B) include: 1) high-dose chemotherapy; or 2) consider additional chemotherapy (see *Acceptable Recurrence Therapies* in the NCCN Guidelines for Less Common Ovarian Histopathologies). Referral of these patients to a tertiary care center for potentially curative therapy is strongly recommended. The NCCN Panel added surveillance recommendations for germ cell tumors for the 2013 update, which are based on the SGO recommendations.<sup>207</sup>

For patients having radiographic evidence of residual tumor (after surgery and chemotherapy) but with normal AFP and beta-HCG, consider surgical resection of the tumor; observation is also an option. Further options depend on which findings are present: residual tumor, benign teratoma, or necrotic tissue (see *Recurrent/Persistent Disease for Malignant Germ Cell Tumors* in the NCCN Guidelines for Less Common Ovarian Histopathologies). For patients having persistently elevated AFP and/or beta-HCG after first-line chemotherapy, recommendations include TIP (paclitaxel, ifosfamide, cisplatin)<sup>308</sup> or high-dose chemotherapy with stem cell support. Referral to a tertiary care center for potentially curative treatment is strongly recommended.<sup>309</sup> Observation is an option (category 2B) for patients with residual malignancy after surgical resection of residual masses; this is an area of continued study and controversy.<sup>297</sup> Others may recommend further chemotherapy (category 2B). There are small series but no major trials in adult patients. Clinical judgment should be used regarding the frequency of imaging.<sup>310</sup>

Patients with recurrent or residual disease after multiple chemotherapeutic regimens for whom no curative options are

considered possible may be treated with a recurrence modality (see *Acceptable Recurrence Therapies for Malignant Germ Cell Tumors* in the NCCN Guidelines for Less Common Ovarian Histopathologies), including TIP, VAC (vincristine, dactinomycin, cyclophosphamide), VeIP (vinblastine, ifosfamide, cisplatin), VIP (etoposide, ifosfamide, cisplatin), cisplatin/etoposide, docetaxel/carboplatin, paclitaxel/carboplatin, paclitaxel/gemcitabine, paclitaxel/ifosfamide, docetaxel, paclitaxel, high-dose chemotherapy, RT, or supportive care only.<sup>309,311-315</sup>

Combination chemotherapy is not recommended for patients with recurrent or residual disease who have no curative options. These recurrence regimens (see *Acceptable Recurrence Therapies for Malignant Germ Cell Tumors* in the NCCN Guidelines for Less Common Ovarian Histopathologies) are not generalizable for all of the uncommon histology tumors; therefore, patients should be referred to tertiary care institutions for treatment.

### Malignant Sex Cord-Stromal Tumors

Malignant stromal tumors are rare and include granulosa cell tumors (most common), granulosa-theca tumors, and Sertoli-Leydig cell tumors; they are typically associated with a good prognosis.<sup>316</sup> Most patients with granulosa tumors present with early-stage disease.<sup>317</sup> It is important to determine whether the sex cord-stromal tumor is benign or malignant (see *Sex Cord Stromal Tumors—WHO Histologic Classification* in the NCCN Guidelines for Less Common Ovarian Histopathologies).<sup>318</sup> The staging system for ovarian and primary peritoneal cancer is also used for sex cord-stromal tumors (see Table 1).

Patients with stage IA or IC sex cord-stromal tumors desiring to preserve their fertility should be treated with fertility-sparing surgery with complete staging.<sup>317,319,320</sup> Complete staging is also recommended for all

other patients; however, lymphadenectomy may be omitted.<sup>321</sup> Patients who choose fertility-sparing surgery should be monitored by ultrasound examinations if necessary; they should be considered for completion surgery (category 2B) after finishing childbearing.

For patients with high-risk stage I tumors (tumor rupture, stage 1C, poorly differentiated tumor, tumor size >10–15 cm<sup>322</sup>), recommendations (all are category 2B) include observation or consideration of platinum-based chemotherapy.<sup>323</sup> Those with surgical findings of low-risk stage I tumor (ie, without high-risk features) should be observed. For patients with granulosa cell tumors who are being observed, inhibin levels can be followed if they were initially elevated (category 2B). For patients with stage II to IV tumors, recommended options (all are category 2B) include RT for limited disease or platinum-based chemotherapy (BEP or paclitaxel/carboplatin regimens are preferred).<sup>324,325</sup>

The NCCN Panel added surveillance recommendations for sex cord-stromal tumors for the 2013 update, which are based on the SGO recommendations.<sup>207</sup> Prolonged surveillance is recommended for granulosa cell tumors, because they can recur years later (eg, 30 years).<sup>302,316,326</sup> For patients with stage II to IV tumors who subsequently have a clinical relapse, options include a clinical trial or recurrence therapy (see *Acceptable Recurrence Therapies for Malignant Sex Cord-Stromal Tumors* in the NCCN Guidelines for Less Common Ovarian Histopathologies).<sup>316,326,327</sup> Note that bevacizumab or leuprolide may be considered for patients with recurrent granulosa cell tumors.<sup>327,328</sup> Secondary cytoreductive surgery may also be considered.

### Carcinosarcoma (Malignant Mixed Müllerian Tumors)

MMMT are rare tumors with a poor prognosis.<sup>329,330</sup> Most pathologists now consider MMT to be a variant of poor risk, poorly differentiated

epithelial ovarian cancer (metaplastic carcinoma). Patients with MMT are not candidates for fertility-sparing surgery. The staging system for ovarian and primary peritoneal cancer is also used for MMT (see Table 1).<sup>329</sup>

Optimal surgical debulking is recommended for patients with MMT (see *Principles of Primary Surgery* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>329,331</sup> After complete surgical staging, patients with stage I to IV MMT at the time of surgery should have postoperative chemotherapy. Patients with stage I to IV MMT or recurrence are treated using the same chemotherapy regimens that are recommended for epithelial ovarian cancer (see *Primary Chemotherapy/Primary Adjuvant Therapy* in the NCCN Guidelines for Epithelial Ovarian Cancer).<sup>332-336</sup> For example, the IP chemotherapy regimen described for ovarian cancer can be used for select patients with MMT.

### Recommended Readings

Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stage III and IV ovarian cancer. *J Clin Oncol* 1992;10:706-717. &

Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *N Engl J Med* 2006;354:34-43. &

Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol* 2006;102:432-439.

Cristea M, Han E, Salmon L, Morgan RJ. Practical considerations in ovarian cancer chemotherapy. *Ther Adv Med Oncol* 2010;2:175-187.

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages III-IV epithelial ovarian cancer. *Gynecol Oncol*. 2006;103:1083-1090.

Fader AN, Rose PG. Role of surgery in ovarian carcinoma. *J Clin Oncol* 2007;25:2873-2883. &

Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. *Cancer* 2007;109:221-227.

Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet* 2009;374:1331-1338.

Morice P, Denschlag D, Rodolakis A, et al. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. *Int J Gynecol Cancer* 2011;21:951-963.

Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: Gynecologic Oncology Group study. *J Clin Oncol* 2003;21:3194-3200. &

Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1992;10:718-726. &

Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant Chemotherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. *J Natl Cancer Inst* 2003;95:105-112.

Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. *Gynecol Oncol* 2006;100:27-32. &

Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. *N Engl J Med* 1990;322:1021-1027. &

& References marked with this symbol provided the basis for the algorithms.

## References

- Chan JK, Cheung MK, Husain A, et al. Patterns and progress in ovarian cancer over 14 years. *Obstet Gynecol* 2006;108:521-528. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16946210>.
- Prat J. New insights into ovarian cancer pathology. *Ann Oncol* 2012;23 Suppl 10:x111-117. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22987944>.
- Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. *CA Cancer J Clin* 2011;61:183-203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21521830>.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23335087>.
- Fleming GF, Ronnett BM, Seidman J. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, eds. *Principles and Practice of Gynecologic Oncology*, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2009:763-836.
- Barakat R, Berchuck A, Markman M, Randall ME. *Principles and Practice of Gynecologic Oncology*, Sixth edition. Philadelphia: Lippincott Williams & Wilkins; 2013.
- Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. *Semin Surg Oncol* 2000;19:3-10. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10883018>.
- Morch LS, Lokkegaard E, Andreasen AH, et al. Hormone therapy and ovarian cancer. *JAMA* 2009;302:298-305. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19602689>.
- Morch LS, Lokkegaard E, Andreasen AH, et al. Hormone therapy and different ovarian cancers: a national cohort study. *Am J Epidemiol* 2012;175:1234-1242. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22517811>.
- Lin HW, Tu YY, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. *Lancet Oncol* 2011;12:900-904. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21835693>.
- van Leeuwen FE, Klip H, Mooij TM, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. *Hum Reprod* 2011;26:3456-3465. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22031719>.
- Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncol* 2012;13:385-394. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22361336>.
- Olsen CM, Nagle CM, Whiteman DC, et al. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. *Endocr Relat Cancer* 2013;20:251-262. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23404857>.
- Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. *J Natl Compr Canc Netw* 2010;8:562-594. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20495085>.
- Walsh CS, Blum A, Walts A, et al. Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. *Gynecol Oncol* 2010;116:516-521. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20034658>.
- Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. *Gynecol Oncol* 2007;107:159-162. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17950381>.
- Shulman LP. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. *Obstet Gynecol Clin*

North Am 2010;37:109-133, Table of Contents. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20494261>.

18. Hereditary breast and ovarian cancer syndrome. *Gynecol Oncol* 2009;113:6-11. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19309638>.

19. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. *Obstet Gynecol* 2009;113:957-966. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19305347>.

20. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. *Gynecol Oncol* 2011;121:353-357. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21324516>.

21. Liu G, Yang D, Sun Y, et al. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. *Pharmacogenomics* 2012;13:1523-1535. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23057551>.

22. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. *JAMA* 2006;296:185-192. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16835424>.

23. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA* 2010;304:967-975. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20810374>.

24. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. *J Natl Cancer Inst* 2009;101:80-87. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19141781>.

25. Powell CB, Chen LM, McLennan J, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. *Int J Gynecol Cancer* 2011;21:846-851. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21670699>.

26. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. *N Engl J Med* 2009;361:170-177. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19587342>.

27. Collins IM, Domchek SM, Huntsman DG, Mitchell G. The tubal hypothesis of ovarian cancer: caution needed. *Lancet Oncol* 2011. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21868285>.

28. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. *Hum Pathol* 2011;42:918-931. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21683865>.

29. Seidman JD, Zhao P, Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. *Gynecol Oncol* 2011;120:470-473. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21159368>.

30. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? *Am J Surg Pathol* 2010;34:1407-1416. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20861711>.

31. Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? *Am J Surg Pathol* 2009;33:376-383. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19011565>.

32. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and



serous cancer prevention. *J Clin Oncol* 2008;26:4160-4165. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18757330>.

33. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. *Am J Surg Pathol* 2007;31:161-169. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17255760>.

34. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. *Am J Surg Pathol* 2006;30:230-236. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16434898>.

35. Semmel DR, Folkins AK, Hirsch MS, et al. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. *Mod Pathol* 2009;22:985-988. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19407856>.

36. Reitsma W, de Bock GH, Oosterwijk JC, et al. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. *Eur J Cancer* 2013;49:132-141. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22921157>.

37. Sieh W, Salvador S, McGuire V, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. *Int J Epidemiol* 2013;42:579-589. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23569193>.

38. Lorusso D, Di Rocco R, Mancini M, Raspagliesi F. High-Grade Serous Tumor Arising from Fallopian Tube in a BRCA Mutation Carrier after Prophylactic Oophorectomy. *Case Rep Oncol* 2013;6:21-24. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23467066>.

39. Tang S, Onuma K, Deb P, et al. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. *Int J Gynecol Pathol* 2012;31:103-110. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22317864>.

40. Tone AA, Salvador S, Finlayson SJ, et al. The role of the fallopian tube in ovarian cancer. *Clin Adv Hematol Oncol* 2012;10:296-306. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22706539>.

41. Mehra K, Mehrad M, Ning G, et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. *Front Biosci (Elite Ed)* 2011;3:625-634. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21196340>.

42. Romero I, Bast RC, Jr. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. *Endocrinology* 2012;153:1593-1602. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22416079>.

43. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. *Cancer* 2007;109:221-227. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17154394>.

44. Andersen MR, Goff BA, Lowe KA, et al. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. *Cancer* 2008;113:484-489. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18615684>.

45. American College of O, Gynecologists Committee on Gynecologic P. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. *Obstet Gynecol* 2011;117:742-746. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21343791>.

46. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. *J Natl Cancer Inst* 2010;102:222-229. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20110551>.

47. Gilbert L, Basso O, Sampalis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the

prospective DOvE pilot project. *Lancet Oncol* 2012;13:285-291. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22257524>.

48. Sharma A, Apostolidou S, Burnell M, et al. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). *Ultrasound Obstet Gynecol* 2012;40:338-344. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22911637>.

49. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Lancet Oncol* 2009;10:327-340. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19282241>.

50. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. *JAMA* 2011;305:2295-2303. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21642681>.

51. Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. *Obstet Gynecol* 2009;113:775-782. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19305319>.

52. Pinsky PF, Zhu C, Skates SJ, et al. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. *Int J Cancer* 2013;132:2127-2133. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23065684>.

53. Valentin L, Jurkovic D, Van Calster B, et al. Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses. *Ultrasound Obstet Gynecol*

2009;34:345-354. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19585547>.

54. Hartge P. Designing early detection programs for ovarian cancer. *J Natl Cancer Inst* 2010;102:3-4. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20042718>.

55. Moyer VA, Force USPST. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med* 2012;157:900-904. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22964825>.

56. Gentry-Maharaj A, Menon U. Screening for ovarian cancer in the general population. *Best Pract Res Clin Obstet Gynaecol* 2012;26:243-256. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22182415>.

57. Smith RA, Brooks D, Cokkinides V, et al. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. *CA Cancer J Clin* 2013;63:88-105. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23378235>.

58. Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. *Gynecol Oncol* 2010;119:7-17. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20692025>.

59. Brown DL, Andreotti RF, Lee SI, et al. ACR appropriateness criteria(c) ovarian cancer screening. *Ultrasound Q* 2010;26:219-223. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21084936>.

60. Horvath G, Jarverud GA, Jarverud S, Horvath I. Human ovarian carcinomas detected by specific odor. *Integr Cancer Ther* 2008;7:76-80. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18505901>.

61. Horvath G, Chilo J, Lindblad T. Different volatile signals emitted by human ovarian carcinoma and healthy tissue. *Future Oncol*



2010;6:1043-1049. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20528240>.

62. Lu KH, Skates S, Bevers TB, et al. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA) [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 5003. Available at:

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/5003](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5003).

63. Skates SJ. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer 2012;22 Suppl 1:S24-26. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22543916>.

64. Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005;99:447-461. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16126262>.

65. Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172-180. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16449677>.

66. du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GFIG OCCC 2004). Ann Oncol 2005;16 Suppl 8:viii7-viii12. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16239238>.

67. Coates RJ, Kolor K, Stewart SL, Richardson LC. Diagnostic markers for ovarian cancer screening: not ready for routine clinical use. Clin Cancer Res 2008;14:7575-7576; author reply 7577-7579. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18948387>.

68. McIntosh M, Anderson G, Drescher C, et al. Ovarian cancer early detection claims are biased. Clin Cancer Res 2008;14:7574; author

reply 7577-7579. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18948385>.

69. Greene MH, Feng Z, Gail MH. The importance of test positive predictive value in ovarian cancer screening. Clin Cancer Res 2008;14:7574; author reply 7577-7579. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18948386>.

70. Buchen L. Cancer: Missing the mark. Nature 2011;471:428-432. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21430749>.

71. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-1072. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18258665>.

72. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-2169. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15781627>.

73. Nolen B, Velikokhatnaya L, Marrangoni A, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;117:440-445. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20334903>.

74. Cramer DW, Bast RC, Jr., Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 2011;4:365-374. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21372036>.

75. Anderson GL, McIntosh M, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010;102:26-38. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20042715>.

76. Mai PL, Wentzensen N, Greene MH. Challenges related to developing serum-based biomarkers for early ovarian cancer detection.



Cancer Prev Res (Phila) 2011;4:303-306. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21372029>.

77. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010.

78. Im SS, Gordon AN, Buttin BM, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005;105:35-41.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15625139>.

79. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol 2007;110:201-214. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17601923>.

80. Dearing AC, Aletti GD, McGree ME, et al. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol 2007;110:841-848. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17906018>.

81. Timmerman D, Testa AC, Bourne T, et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 2008;31:681-690. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18504770>.

82. Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol 2010;194:311-321. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20093590>.

83. Harris RD, Javitt MC, Glanc P, et al. ACR Appropriateness Criteria(R) clinically suspected adnexal mass. Ultrasound Q 2013;29:79-86. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23358212>.

84. Dodge JE, Covens AL, Lacchetti C, et al. Management of a suspicious adnexal mass: a clinical practice guideline. Curr Oncol 2012;19:e244-257. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22876153>.

85. Gregory JJ, Jr., Finlay JL. Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers. Drugs 1999;57:463-467. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10235686>.

86. Schneider DT, Calaminus G, Reinhard H, et al. Primary mediastinal germ cell tumors in children and adolescents: results of the German cooperative protocols MAKEI 83/86, 89, and 96. J Clin Oncol 2000;18:832-839. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10673525>.

87. Kawai M, Furuhashi Y, Kano T, et al. Alpha-fetoprotein in malignant germ cell tumors of the ovary. Gynecol Oncol 1990;39:160-166.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1699854>.

88. Yamamoto Y, Oguri H, Yamada R, et al. Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Int J Gynaecol Obstet 2008;102:124-127. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18423470>.

89. Castellucci P, Perrone AM, Picchio M, et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun 2007;28:589-595.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17625380>.

90. Risum S, Hogdall C, Loft A, et al. The diagnostic value of PET/CT for primary ovarian cancer--a prospective study. Gynecol Oncol 2007;105:145-149. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17229460>.

91. Cannistra SA, Gershenson DM, Recht A. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita Jr. VT, Lawrence TS, Rosenberg SA, et al., eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.

92. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. *Lancet* 2001;357:176-182. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11213094>.
93. DeVita VT, Lawrence TS, Rosenberg SA, DePino RA. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology (ed 8th). Philadelphia: Lippincott Williams & Wilkins; 2008.
94. Young RH. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. *Adv Anat Pathol* 2007;14:149-177. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17452813>.
95. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. *Am J Surg Pathol* 2003;27:281-292. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12604884>.
96. Kim KA, Park CM, Lee JH, et al. Benign ovarian tumors with solid and cystic components that mimic malignancy. *AJR Am J Roentgenol* 2004;182:1259-1265. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15100129>.
97. Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. *Obstet Gynecol* 2011;118:280-288. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21775843>.
98. Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. *Gynecol Oncol* 2011;121:487-491. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21420727>.
99. Molina R, Escudero JM, Auge JM, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. *Tumour Biol* 2011;32:1087-1095. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21863264>.
100. Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. *Br J Cancer* 2011;104:863-870. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21304524>.
101. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. *Pathology* 2011;43:420-432. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21716157>.
102. Kobel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. *Int J Gynecol Pathol* 2010;29:203-211. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20407318>.
103. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. *Int J Gynecol Pathol* 2004;23:41-44. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14668549>.
104. Whitney CW, Spirito N. Gynecologic Oncology Group Surgical Procedures Manual. Philadelphia: Gynecologic Oncology Group; 2009.
105. Schlaerth AC, Chi DS, Poyner EA, et al. Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. *Int J Gynecol Cancer* 2009;19:1199-1204. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19823055>.
106. Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. *Gynecol Oncol* 2002;87:1-7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12468335>.
107. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. *J Clin Oncol* 2007;25:2873-2883. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17617518>.



108. Wright JD, Shah M, Mathew L, et al. Fertility preservation in young women with epithelial ovarian cancer. *Cancer* 2009;115:4118-4126. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19670446>.

109. Satoh T, Hatae M, Watanabe Y, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. *J Clin Oncol* 2010;28:1727-1732. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20194858>.

110. Gershenson DM. Treatment of ovarian cancer in young women. *Clin Obstet Gynecol* 2012;55:65-74. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22343230>.

111. Stier EA, Barakat RR, Curtin JP, et al. Laparotomy to complete staging of presumed early ovarian cancer. *Obstet Gynecol* 1996;87:737-740. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8677077>.

112. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *J Clin Oncol* 2002;20:1248-1259. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11870167>.

113. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. *Gynecol Oncol* 2006;103:1083-1090. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16890277>.

114. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). *Cancer* 2009;115:1234-1244. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19189349>.

115. Schorge JO, Garrett LA, Goodman A. Cytoreductive surgery for advanced ovarian cancer: quo vadis? *Oncology (Williston Park)* 2011;25:928-934. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22010391>.

116. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. *Gynecol Oncol* 2009;112:265-274. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18937969>.

117. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. *Obstet Gynecol* 2006;107:77-85. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16394043>.

118. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. *Gynecol Oncol* 2008;108:276-281. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18063020>.

119. Elattar A, Bryant A, Winter-Roach BA, et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer. *Cochrane Database Syst Rev* 2011:CD007565. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21833960>.

120. Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. *J Natl Cancer Inst* 2005;97:560-566. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15840878>.

121. Aletti GD, Powless C, Bakkum-Gamez J, et al. Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. *Gynecol Oncol* 2009;114:32-36. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19361840>.

122. Committee on Practice B-G. ACOG Practice Bulletin No. 126: Management of gynecologic issues in women with breast cancer.

Obstet Gynecol 2012;119:666-682. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22353976>.

123. Barton DL, Loprinzi C, Gostout B. Current management of menopausal symptoms in cancer patients. Oncology (Williston Park) 2002;16:67-72, 74; discussion 75-66, 79-80. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/11831612>.

124. Jenkins MR, Sikin AL. Update on nonhormonal approaches to menopausal management. Cleve Clin J Med 2008;75 Suppl 4:S17-24. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18697262>.

125. du Bois A, Reuss A, Harter P, et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 2010;28:1733-1739. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20194855>.

126. Wimberger P, Lehmann N, Kimmig R, et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007;106:69-74. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17397910>.

127. Chi DS, Bristow RE, Armstrong DK, Karlan BY. Is the easier way ever the better way? J Clin Oncol 2011;29:4073-4075. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/21931018>.

128. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J Clin Oncol 2011;29:4076-4078. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/21931032>.

129. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med

2004;351:2489-2497. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15590951>.

130. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-634. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/7845426>.

131. Colombo PE, Mourregot A, Fabbro M, et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol 2009;35:135-143. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18289825>.

132. Rauh-Hain JA, Rodriguez N, Growdon WB, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol 2012;19:959-965. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/21994038>.

133. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-953. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20818904>.

134. Steed H, Oza AM, Murphy J, et al. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer. Int J Gynecol Cancer 2006;16 Suppl 1:47-53. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16515567>.

135. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2009:CD006014. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19160263>.

136. Tiersten AD, Liu PY, Smith HO, et al. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian,

fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. *Gynecol Oncol* 2009;112:444-449. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19138791>.

137. Vandenput I, Van Calster B, Capoen A, et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? *Br J Cancer* 2009;101:244-249. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19568245>.

138. Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). *Gynecol Oncol* 2012;124:10-14. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21917306>.

139. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *N Engl J Med* 2006;354:34-43. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16394300>.

140. Dewdney SB, Rimel BJ, Reinhart AJ, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. *Gynecol Oncol* 2010;119:18-21. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20673970>.

141. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. *N Engl J Med* 1990;322:1021-1027. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2181310>.

142. Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. *Cochrane Database Syst Rev* 2009:CD004706. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19588360>.

143. Hogberg T, Glimelius B, Nygren P, Care SB-gSCoTAiH. A systematic overview of chemotherapy effects in ovarian cancer. *Acta Oncol* 2001;40:340-360. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11441940>.

144. Cristea M, Han E, Salmon L, Morgan RJ. Practical considerations in ovarian cancer chemotherapy. *Ther Adv Med Oncol* 2010;2:175-187. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21789133>.

145. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. *J Clin Oncol* 2006;24:988-994. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16461779>.

146. Marth C, Walker JL, Barakat RR, et al. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. *Cancer* 2007;109:645-649. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17238177>.

147. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 2003;21:3194-3200. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12860964>.

148. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. *J Natl Cancer Inst* 2004;96:1682-1691. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15547181>.

149. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med* 1996;334:1-6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7494563>.

150. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group

study. *Gynecol Oncol* 2006;102:432-439. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16860852>.

151. Chan JK, Tian C, Fleming GF, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. *Gynecol Oncol* 2010;116:301-306. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19945740>.

152. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. *J Clin Oncol* 2011;29:3628-3635. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21844495>.

153. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet* 2009;374:1331-1338. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19767092>.

154. Barlin JN, Dao F, Zgheib NB, et al. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. *Gynecol Oncol* 2012;125:621-624. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22446622>.

155. Markman M. Management of ovarian cancer. An impressive history of improvement in survival and quality of life. *Oncology (Williston Park)* 2006;20:347-354; discussion 354, 357-348, 364 passim. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16683414>.

156. Wenzel LB, Huang HQ, Armstrong DK, et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. *J Clin Oncol* 2007;25:437-443. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17264340>.

157. Landrum LM, Hyde J, Jr., Mannel RS, et al. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. *Gynecol Oncol* 2011;122:527-531. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21664657>.

158. Markman M. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer. *Cancer J* 2009;15:105-109. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19390303>.

159. Zeimet AG, Reimer D, Radl AC, et al. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. *Anticancer Res* 2009;29:2803-2808. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19596965>.

160. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. *Gynecol Oncol* 2006;100:27-32. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16368440>.

161. Rowan K. Intraperitoneal therapy for ovarian cancer: why has it not become standard? *J Natl Cancer Inst* 2009;101:775-777. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19470952>.

162. Gore M, du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. *J Clin Oncol* 2006;24:4528-4530. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17008689>.

163. Armstrong DK, Brady MF. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. *J Clin Oncol* 2006;24:4531-4533. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17008690>.

164. Ozols RF, Bookman MA, du Bois A, et al. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. *Gynecol Oncol* 2006;103:1-6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16904166>.

165. Landrum LM, Java J, Mathews CA, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study. *Gynecol Oncol* 2013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23578540>.

166. Lesnock JL, Darcy KM, Tian C, et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. *Br J Cancer* 2013;108:1231-1237. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23462720>.

167. Katsumata N, Yasuda M, Isonishi S, et al. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial [abstract]. *J Clin Oncol* 2012;30(Suppl 15):Abstract 5003. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/30/15\\_suppl/5003](http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5003).

168. Bookman MA. Dose-dense chemotherapy in advanced ovarian cancer. *Lancet* 2009;374:1303-1305. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19767094>.

169. Abaid LN, Micha JP, Rettenmaier MA, et al. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma. *Cancer Chemother Pharmacol* 2013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23660691>.

170. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study [abstract]. *J Clin Oncol* 2010;28(Suppl 18):Abstract LBA1. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/28/18\\_suppl/LBA1](http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA1).

171. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med*

2011;365:2473-2483. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22204724>.

172. Hall M, Gourley C, McNeish I, et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. *Br J Cancer* 2013;108:250-258. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23385789>.

173. Kristensen G, Perren T, Qian W, et al. Result of interim analysis of overall survival in the GIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer [abstract]. *J Clin Oncol* 2011;29(Suppl 18):Abstract LBA5006. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/29/18\\_suppl/LBA5006](http://meeting.ascopubs.org/cgi/content/abstract/29/18_suppl/LBA5006).

174. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med* 2011;365:2484-2496. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22204725>.

175. Morgan RJ, Jr., Alvarez RD, Armstrong DK, et al. Ovarian cancer, version 3.2012. *J Natl Compr Canc Netw* 2012;10:1339-1349. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23138163>.

176. Stark D, Nankivell M, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. *Lancet Oncol* 2013;14:236-243. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23333117>.

177. Monk BJ, Huang HQ, Burger RA, et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. *Gynecol Oncol* 2013;128:573-578. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23219660>.

178. Friedlander ML, Stockler MR, Butow P, et al. Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian



Cancer: Time to Think Differently? J Clin Oncol 2013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23669225>.

179. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29:3798-3804. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21859991>.

180. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:1419-1425. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19224846>.

181. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-2465. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12829663>.

182. Pecorelli S, Favalli G, Gadducci A, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol 2009;27:4642-4648. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19704064>.

183. Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010;65:1357-1366. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20716314>.

184. Romano A, Torres MJ, Castells M, et al. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol 2011;127:S67-73. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21354502>.

185. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574-580. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18502492>.

186. Dizon DS, Sabbatini PJ, Aghajanian C, et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002;84:378-382. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11855873>.

187. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006;47:373-380. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16546624>.

188. Manivannan V, Decker WW, Stead LG, et al. Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. Int J Emerg Med 2009;2:3-5. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19390910>.

189. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-609. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17522249>.

190. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424-436. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11405181>.

191. Navo M, Kunthur A, Badell ML, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 2006;103:608-613. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16797060>.

192. Markman M, Zanotti K, Peterson G, et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. *J Clin Oncol* 2003;21:4611-4614. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14673050>.

193. Simons FE, Arduso LR, Bilo MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. *World Allergy Organ J* 2011;4:13-37. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23268454>.

194. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. *Gynecol Oncol* 2005;99:393-399. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16054201>.

195. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. *Gynecol Oncol* 2004;95:370-376. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15491759>.

196. Markman M, Hsieh F, Zanotti K, et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. *J Cancer Res Clin Oncol* 2004;130:25-28. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14564516>.

197. O'Cearbhaill R, Zhou Q, Iasonos A, et al. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. *Gynecol Oncol* 2010;116:326-331. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19944454>.

198. Gomez R, Harter P, Luck HJ, et al. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. *Int J Gynecol Cancer* 2009;19:1284-1287. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19823066>.

199. Patil SU, Long AA, Ling M, et al. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. *J Allergy Clin Immunol* 2012;129:443-447. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22099941>.

200. Corn BW, Lanciano RM, Boente M, et al. Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure. *Cancer* 1994;74:2979-2983. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7525039>.

201. Tinger A, Waldron T, Peluso N, et al. Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. *Int J Radiat Oncol Biol Phys* 2001;51:1256-1263. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11728685>.

202. Smith SC, Koh WJ. Palliative radiation therapy for gynaecological malignancies. *Best Pract Res Clin Obstet Gynaecol* 2001;15:265-278. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11358401>.

203. Yan J, Milosevic M, Fyles A, et al. A hypofractionated radiotherapy regimen (0-7-21) for advanced gynaecological cancer patients. *Clin Oncol (R Coll Radiol)* 2011;23:476-481. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21482082>.

204. Teckie S, Makker V, Tabar V, et al. Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival. *Radiat Oncol* 2013;8:36. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23414446>.

205. Fulham MJ, Carter J, Baldey A, et al. The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. *Gynecol Oncol* 2009;112:462-468. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19150121>.

206. Risum S, Hogdall C, Markova E, et al. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of

patients for secondary cytoreductive surgery. *Int J Gynecol Cancer* 2009;19:600-604. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19509556>.

207. Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. *Am J Obstet Gynecol* 2011;204:466-478. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21752752>.

208. Bhosale P, Peungjesada S, Wei W, et al. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. *Int J Gynecol Cancer* 2010;20:936-944. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20683399>.

209. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. *Lancet* 2010;376:1155-1163. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20888993>.

210. Rustin G, van der Burg M, Griffin C, et al. Early versus delayed treatment of relapsed ovarian cancer. *Lancet* 2011;377:380-381. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21277438>.

211. Rustin GJ, van der Burg ME, MRC obo, EORTC Collaborators. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) [abstract]. *J Clin Oncol* 2009;27(Suppl 18S):Abstract 1. Available at: <http://meeting.ascopubs.org/cgi/content/abstract/27/18S/1>.

212. Miller RE, Rustin GJ. How to follow-up patients with epithelial ovarian cancer. *Curr Opin Oncol* 2010;22:498-502. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20498597>.

213. Markman M, Petersen J, Belland A, Burg K. CA-125 monitoring in ovarian cancer: patient survey responses to the results of the

MRC/EORTC CA-125 Surveillance Trial. *Oncology* 2010;78:1-2. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20215782>.

214. Morris RT, Monk BJ. Ovarian cancer: relevant therapy, not timing, is paramount. *Lancet* 2010;376:1120-1122. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20888975>.

215. Karam AK, Karlan BY. Ovarian cancer: the duplicity of CA125 measurement. *Nat Rev Clin Oncol* 2010;7:335-339. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20368726>.

216. Bast RC, Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. *Cancer* 2010;116:2850-2853. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20564390>.

217. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. *Cancer* 1991;68:269-271. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2070324>.

218. Van Der Velden J, Gitsch G, Wain GV, et al. Tamoxifen in patients with advanced epithelial ovarian cancer. *Int J Gynecol Cancer* 1995;5:301-305. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11578494>.

219. Markman M, Webster K, Zanotti K, et al. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. *Gynecol Oncol* 2004;93:390-393. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15099951>.

220. Griffiths RW, Zee YK, Evans S, et al. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. *Int J Gynecol Cancer* 2011;21:58-65. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21178570>.

221. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10655437>.

222. Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80 mg/m<sup>2</sup>) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006;101:436-440. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16325893>.

223. Sharma R, Graham J, Mitchell H, et al. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009;100:707-712. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19223898>.

224. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-393. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1999708>.

225. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007;14:195-208. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17938703>.

226. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-2106. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12826431>.

227. Courtney A, Nemcek AA, Jr., Rosenberg S, et al. Prospective evaluation of the PleurX catheter when used to treat recurrent ascites associated with malignancy. J Vasc Interv Radiol 2008;19:1723-1731. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18951041>.

228. Iyengar TD, Herzog TJ. Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter. Am J Hosp Palliat Care 2002;19:35-38. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12171424>.

229. Brooks RA, Herzog TJ. Long-term semi-permanent catheter use for the palliation of malignant ascites. Gynecol Oncol 2006;101:360-362. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16499957>.

230. White J, Carolan-Rees G. PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE Medical Technology Guidance. Appl Health Econ Health Policy 2012;10:299-308. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22779402>.

231. Roeland E, von Gunten CF. Current concepts in malignant bowel obstruction management. Curr Oncol Rep 2009;11:298-303. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19508835>.

232. Baron TH. Interventional palliative strategies for malignant bowel obstruction. Curr Oncol Rep 2009;11:293-297. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19508834>.

233. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88:144-153. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10618617>.

234. Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 2005;92:1026-1032. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15770211>.

235. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;106:1933-1939. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16572412>.

236. Strauss HG, Henze A, Teichmann A, et al. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. *Gynecol Oncol* 2007;104:612-616. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17069876>.

237. Kushner DM, Connor JP, Sanchez F, et al. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. *Gynecol Oncol* 2007;105:358-364. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17258800>.

238. Rose PG. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. *Int J Gynecol Cancer* 2005;15 Suppl 1:18-22. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15839954>.

239. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. *J Clin Oncol* 2006;24:4699-4707. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16966687>.

240. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. *J Clin Oncol* 2010;28:3323-3329. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20498395>.

241. Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. *Onco Targets Ther* 2013;6:107-118. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23459506>.

242. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. *Gynecol Oncol* 2004;95:1-8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15385103>.

243. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. *J Clin Oncol* 2008;26:890-896. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18281662>.

244. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. *J Clin Oncol* 2007;25:2811-2818. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17602086>.

245. Rothenberg ML, Liu PY, Wilczynski S, et al. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. *Gynecol Oncol* 2004;95:506-512. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15581954>.

246. Bajetta E, Di Leo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. *J Clin Oncol* 1996;14:2546-2551. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8823334>.

247. Markman M. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. *Cancer Manag Res* 2011;3:219-225. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21792330>.

248. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 1998;16:405-410. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9469322>.

249. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2003;88:130-135. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12586591>.

250. Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant

ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. *J Clin Oncol* 2009;27:2686-2691. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19332726>.

251. Sehouli J, Stengel D, Harter P, et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. *J Clin Oncol* 2011;29:242-248. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21115872>.

252. Herzog TJ, Sill MW, Walker JL, et al. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). *Gynecol Oncol* 2011;120:454-458. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21168198>.

253. Teneriello MG, Tseng PC, Crozier M, et al. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. *J Clin Oncol* 2009;27:1426-1431. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19224848>.

254. Alberts DS, Jiang C, Liu PY, et al. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. *Int J Gynecol Cancer* 2004;14:224-228. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15086720>.

255. Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. *J Clin Oncol* 1992;10:243-248. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1732425>.

256. Bidus MA, Webb JC, Seidman JD, et al. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. *Gynecol Oncol* 2006;102:5-7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16697451>.

257. Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. *Cancer* 2006;107:83-89. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16736514>.

258. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. *J Clin Oncol* 2007;25:5165-5171. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18024863>.

259. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. *J Clin Oncol* 2007;25:5180-5186. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18024865>.

260. Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. *Gynecol Oncol* 2007;107:118-123. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17658587>.

261. Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) [abstract]. *J Clin Oncol* 2011;29(Suppl 18):Abstract LBA5007. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/29/18\\_suppl/LBA5007](http://meeting.ascopubs.org/cgi/content/abstract/29/18_suppl/LBA5007).

262. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *J Clin Oncol* 2012;30:2039-2045. Available at: <http://www.ncbi.nlm.nih.gov/pubmed22529265>.

263. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus

chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [abstract]. *J Clin Oncol* 2012;30(Suppl 15):Abstract LBA5002.

Available at:

[http://meeting.ascopubs.org/cgi/content/abstract/30/15\\_suppl/LBA5002](http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/LBA5002).

264. Emile G, Chauvenet L, Tigaud JM, et al. A clinical experience of single agent bevacizumab in relapsing ovarian cancer. *Gynecol Oncol* 2013;129:459-462. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23474345>.

265. Ferrandina G, Ludovisi M, De Vincenzo R, et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. *Ann Oncol* 2007;18:1348-1353.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17470449>.

266. Wolf JK, Bodurka DC, Verschraegen C, et al. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. *Gynecol Oncol* 2006;102:468-474.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16516276>.

267. Markman M, Iseminger KA, Hatch KD, et al. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. *Gynecol Oncol* 1996;62:4-6. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8690289>.

268. Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer. *Expert Rev Anticancer Ther* 2006;6:43-47. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16375643>.

269. Papadimitriou CA, Markaki S, Siapkarakas J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. *Oncology* 2004;66:112-117. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15138362>.

270. Bowman A, Gabra H, Langdon SP, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive

subgroup. *Clin Cancer Res* 2002;8:2233-2239. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12114425>.

271. del Carmen MG, Fuller AF, Matulonis U, et al. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. *Gynecol Oncol* 2003;91:596-602. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/14675683>.

272. Ramirez PT, Schmeler KM, Milam MR, et al. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. *Gynecol Oncol* 2008;110:56-59.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18457865>.

273. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol* 2011;12:852-861.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21862407>.

274. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet* 2010;376:245-251. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20609468>.

275. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol* 2010;28:2512-2519.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20406929>.

276. Gelmon KA, Hirte HW, Robidoux A, et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [abstract]. *J Clin Oncol* 2010;28(Suppl 15):Abstract 3002.

Available at:

[http://meeting.ascopubs.org/cgi/content/abstract/28/15\\_suppl/3002](http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3002).

277. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med* 2012;366:1382-1392. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22452356>.

278. Matsuo K, Eno ML, Im DD, et al. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. *Gynecol Oncol* 2010;116:61-65. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19840886>.

279. Karam AK, Chiang JW, Fung E, et al. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. *Gynecol Oncol* 2009;114:246-252. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19500821>.

280. Burstein HJ, Mangu PB, Somerfield MR, et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. *J Clin Oncol* 2011;29:3328-3330. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21788567>.

281. Cadron I, Leunen K, Van Gorp T, et al. Management of borderline ovarian neoplasms. *J Clin Oncol* 2007;25:2928-2937. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17617524>.

282. Barakat RR, Benjamin I, Lewis JL, Jr., et al. Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. *Gynecol Oncol* 1995;59:390-393. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8522261>.

283. Leake JF, Currie JL, Rosenshein NB, Woodruff JD. Long-term follow-up of serous ovarian tumors of low malignant potential. *Gynecol Oncol* 1992;47:150-158. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/1468692>.

284. Barnhill DR, Kurman RJ, Brady MF, et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential:

a Gynecologic Oncology Group study. *J Clin Oncol* 1995;13:2752-2756.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7595734>.

285. Gershenson DM, Silva EG. Serous ovarian tumors of low malignant potential with peritoneal implants. *Cancer* 1990;65:578-585.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2297647>.

286. Sutton GP, Bundy BN, Omura GA, et al. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). *Gynecol Oncol* 1991;41:230-233.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1869100>.

287. Morice P, Denschlag D, Rodolakis A, et al. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. *Int J Gynecol Cancer* 2011;21:951-963. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21697684>.

288. Wingo SN, Knowles LM, Carrick KS, et al. Retrospective cohort study of surgical staging for ovarian low malignant potential tumors. *Am J Obstet Gynecol* 2006;194:e20-22. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16647891>.

289. Winter WE, 3rd, Kucera PR, Rodgers W, et al. Surgical staging in patients with ovarian tumors of low malignant potential. *Obstet Gynecol* 2002;100:671-676. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12383532>.

290. Shih KK, Zhou QC, Aghajanian C, et al. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. *Gynecol Oncol* 2010;119:270-273. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20719369>.

291. Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. *Cancer* 1996;78:278-286. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8674004>.



292. Ayhan A, Celik H, Taskiran C, et al. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. *Eur J Gynaecol Oncol* 2003;24:223-232. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12807228>.

293. Zanetta G, Bonazzi C, Cantu M, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. *J Clin Oncol* 2001;19:1015-1020. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11181664>.

294. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. *J Clin Oncol* 2006;24:2917-2931. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16651642>.

295. Lai CH, Chang TC, Hsueh S, et al. Outcome and prognostic factors in ovarian germ cell malignancies. *Gynecol Oncol* 2005;96:784-791. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15721426>.

296. Mangili G, Sigismondi C, Gadducci A, et al. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study. *Int J Gynecol Cancer* 2011. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21795985>.

297. Gershenson DM. Management of ovarian germ cell tumors. *J Clin Oncol* 2007;25:2938-2943. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17617525>.

298. Gershenson DM, Morris M, Cangir A, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. *J Clin Oncol* 1990;8:715-720. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/1690272>.

299. Zanagnolo V, Sartori E, Galleri G, et al. Clinical review of 55 cases of malignant ovarian germ cell tumors. *Eur J Gynaecol Oncol* 2004;25:315-320. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15171308>.

300. Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. *Cancer* 2000;89:391-398. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10918171>.

301. Mangili G, Scarfone G, Gadducci A, et al. Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). *Gynecol Oncol* 2010;119:48-52. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20599258>.

302. Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. *Cancer Treat Rev* 2008;34:427-441. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18378402>.

303. Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. *Obstet Gynecol* 2003;101:251-257. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12576247>.

304. Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. *Gynecol Oncol* 2005;97:489-496. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15863149>.

305. Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. *J Clin Oncol* 1994;12:701-706. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/7512129>.

306. Kang H, Kim TJ, Kim WY, et al. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. *Gynecol Oncol* 2008;111:106-110. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18656249>.

307. Williams SD, Kauderer J, Burnett AF, et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. *Gynecol Oncol* 2004;95:496-499. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15581952>.

308. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. *J Clin Oncol* 2005;23:6549-6555. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16170162>.

309. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. *N Engl J Med* 2007;357:340-348. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17652649>.

310. Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. *N Engl J Med* 2007;357:2277-2284. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18046031>.

311. Loehrer PJ, Sr., Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. *J Clin Oncol* 1998;16:2500-2504. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9667270>.

312. Hinton S, Catalano P, Einhorn LH, et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. *J Clin Oncol* 2002;20:1859-1863. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11919245>.

313. Nichols CR, Roth BJ, Loehrer PJ, et al. Salvage chemotherapy for recurrent germ cell cancer. *Semin Oncol* 1994;21:102-108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7992061>.

314. Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ

cell tumors: final analysis of an intergroup trial. *Cancer* 2003;97:1869-1875. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12673712>.

315. Slayton RE, Park RC, Silverberg SG, et al. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). *Cancer* 1985;56:243-248. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2988740>.

316. Colombo N, Parma G, Zanagnolo V, Insinga A. Management of ovarian stromal cell tumors. *J Clin Oncol* 2007;25:2944-2951. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17617526>.

317. Lee IH, Choi CH, Hong DG, et al. Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study. *J Gynecol Oncol* 2011;22:188-195. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21998762>.

318. Tavassoéli FA, Devilee P, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.

319. Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women. *Gynecol Oncol* 2007;104:396-400. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17030354>.

320. Wolf J, Brown J. Management of stromal tumors of the ovary: ASCO; 2008.

321. Brown J, Sood AK, Deavers MT, et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted? *Gynecol Oncol* 2009;113:86-90. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19162310>.

322. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. *J Clin Oncol* 2003;21:1180-1189. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12637488>.

323. Schneider DT, Calaminus G, Wessalowski R, et al. Ovarian sex cord-stromal tumors in children and adolescents. *J Clin Oncol* 2003;21:2357-2363. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12805338>.

324. Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. *Gynecol Oncol* 1999;72:131-137. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10021290>.

325. Pautier P, Gutierrez-Bonnaire M, Rey A, et al. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. *Int J Gynecol Cancer* 2008;18:446-452. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18494093>.

326. Teoh D, Freedman R, Soliman PT. Nearly 30 years of treatment for recurrent granulosa cell tumor of the ovary: a case report and review of the literature. *Case Rep Oncol* 2010;3:14-18. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20740152>.

327. Fishman A, Kudelka AP, Tresukosol D, et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. *J Reprod Med* 1996;41:393-396. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8799913>.

328. Tao X, Sood AK, Deavers MT, et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. *Gynecol Oncol* 2009;114:431-436. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19524286>.

329. del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. *Gynecol Oncol* 2012;125:271-277. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22155675>.

330. Mano MS, Rosa DD, Azambuja E, et al. Current management of ovarian carcinosarcoma. *Int J Gynecol Cancer* 2007;17:316-324. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17362309>.

331. Brown E, Stewart M, Rye T, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. *Cancer* 2004;100:2148-2153. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15139057>.

332. Duska LR, Garrett A, Eltabbakh GH, et al. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. *Gynecol Oncol* 2002;85:459-463. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12051874>.

333. Inthasorn P, Beale P, Dalrymple C, Carter J. Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. *Aust N Z J Obstet Gynaecol* 2003;43:61-64. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12755351>.

334. Rauh-Hain JA, Growdon WB, Rodriguez N, et al. Carcinosarcoma of the ovary: a case-control study. *Gynecol Oncol* 2011;121:477-481. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21420726>.

335. Leiser AL, Chi DS, Ishill NM, Tew WP. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. *Gynecol Oncol* 2007;105:657-661. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17395252>.

336. Loizzi V, Cormio G, Camporeale A, et al. Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature. *Oncology* 2011;80:102-106. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21677454>.